British Association of Dermatologists
93rd Annual Meeting
ACC Liverpool
9th – 11th July 2013

Final Programme
**Picato®, Actinic Keratosis (AK)**

"Picato®" is licensed for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.

The 93rd Annual Meeting of the British Association of Dermatologists, ACC Liverpool

**18:15 – 19:00, Wednesday 10th July 2013, Hall 3B**

Come and join this evening meeting to discuss current challenges surrounding the management of actinic keratosis and how Picato®, a new treatment for actinic keratosis, may help to manage the condition in your patients.

This interactive symposium will be chaired by Dr John Lear, Consultant Dermatologist, Manchester Royal Infirmary and Hope Hospital, Salford, and will review current treatments and clinical data for Picato®. The patient experience will also be featured.

---

### Picato® and the Patient

**Abbreviated Prescribing Information for Picato®**

**Indication:**

Abbreviated Prescribing Information for Picato®

**Posology:**

be applied once daily to affected area for 3 consecutive days. Application to the trunk

**Dosage and administration:**

Application to the face and scalp (150 mcg/g): One tube should be applied to one treatment area of 25 cm² (eg 5 cm x 5 cm); this

The contents of one tube covers a treatment area of 25 cm² (eg 5 cm x 5 cm); this

**Posology:**

Application to the face and scalp (150 mcg/g): One tube should be applied to one treatment area of 25 cm² (eg 5 cm x 5 cm); this

**Side effects:**

Most frequently reported adverse reactions (AEs) are LSRs. Following

**Precautions and warnings:**

Avoid contact with eyes. If accidental exposure occurs,

**Legal category:**

Picato® 150 mcg/g gel – EU/1/12/796/001; Picato® 500 mcg/g gel – EU/1/12/796/002. LEO Pharma A/S, Ballerup, Denmark.

**Drug interactions:**

Interactions with systemically absorbed medicinal products for malignancy should be biopsied to determine appropriate treatment.

---

### Index

<table>
<thead>
<tr>
<th>Page Number</th>
<th>MONDAY OVERVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Accompanying persons</td>
</tr>
<tr>
<td>6</td>
<td>App</td>
</tr>
<tr>
<td>12</td>
<td>Additional meetings</td>
</tr>
<tr>
<td>6</td>
<td>Badges</td>
</tr>
<tr>
<td>6</td>
<td>Banking</td>
</tr>
<tr>
<td>6</td>
<td>Business Services</td>
</tr>
<tr>
<td>6</td>
<td>Catering</td>
</tr>
<tr>
<td>6</td>
<td>Certificates of attendance</td>
</tr>
<tr>
<td>6</td>
<td>Cloakroom</td>
</tr>
<tr>
<td>11</td>
<td>Committee meetings</td>
</tr>
<tr>
<td>6</td>
<td>Continuing Professional Development (CPD)</td>
</tr>
<tr>
<td>6</td>
<td>Exhibition</td>
</tr>
<tr>
<td>6</td>
<td>Exhibitor Directory</td>
</tr>
<tr>
<td>62 - 63</td>
<td>Exhibition quiz</td>
</tr>
<tr>
<td>62 - 63</td>
<td>First aid</td>
</tr>
<tr>
<td>6</td>
<td>Focus Sessions</td>
</tr>
<tr>
<td>51</td>
<td>Map of Liverpool</td>
</tr>
<tr>
<td>72</td>
<td>Meetings Calendar</td>
</tr>
<tr>
<td>73</td>
<td>Messages</td>
</tr>
<tr>
<td>4</td>
<td>Organising Committees</td>
</tr>
<tr>
<td>7</td>
<td>Parking</td>
</tr>
<tr>
<td>7</td>
<td>Patient support groups</td>
</tr>
<tr>
<td>7</td>
<td>Payment of registration fees</td>
</tr>
<tr>
<td>7</td>
<td>Poster exhibition</td>
</tr>
<tr>
<td>53 - 57</td>
<td>Posters</td>
</tr>
<tr>
<td>7</td>
<td>Registration desk</td>
</tr>
<tr>
<td>7</td>
<td>Restaurants</td>
</tr>
<tr>
<td>7</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>58 - 61</td>
<td>Social events</td>
</tr>
<tr>
<td>10</td>
<td>Speaker preview</td>
</tr>
<tr>
<td>8</td>
<td>Special interest groups</td>
</tr>
<tr>
<td>8</td>
<td>Taxis</td>
</tr>
<tr>
<td>8</td>
<td>Transport - to and from Liverpool</td>
</tr>
<tr>
<td>9</td>
<td>Venue Plan</td>
</tr>
<tr>
<td>5</td>
<td>Welcome to Liverpool</td>
</tr>
<tr>
<td>14</td>
<td>Programme index</td>
</tr>
</tbody>
</table>

---

**Wednesday Overview**

<table>
<thead>
<tr>
<th>Page Number</th>
<th>TUESDAY OVERVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>CPCs - Joint BAD / BSD</td>
</tr>
<tr>
<td>20 - 21</td>
<td>Plenary Session pm</td>
</tr>
<tr>
<td>21 - 22</td>
<td>British Society for Skin Care In Immunocompromised Individuals (BSSCI)</td>
</tr>
<tr>
<td>23 - 24</td>
<td>British Telemedicine Society (BTS)</td>
</tr>
<tr>
<td>26 - 27</td>
<td>British Society of Cutaneous Allergy (BSCA)</td>
</tr>
<tr>
<td>28 - 30</td>
<td>British Society for Paediatric Dermatology (BSDS)</td>
</tr>
<tr>
<td>31 - 32</td>
<td>Historical</td>
</tr>
<tr>
<td>33 - 35</td>
<td>British Society for Dermatopathology (BSD)</td>
</tr>
</tbody>
</table>

---

**Thursday Overview**

<table>
<thead>
<tr>
<th>Page Number</th>
<th>THURSDAY OVERVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>Plenary Session Professor’s &amp; Registrars’ forum</td>
</tr>
<tr>
<td>50 - 51</td>
<td>Focus Session</td>
</tr>
<tr>
<td>52</td>
<td>CPD update</td>
</tr>
<tr>
<td>52</td>
<td>KEYNOTE LECTURES</td>
</tr>
</tbody>
</table>

---

**Tuesday**

Professor Chris Denton 22
Professor Wendy Reid 22

---

**Wednesday**

Professor Irwin McLean 38

---

**Thursday**

Professor Richard Gallo 51
Professor Nicholas Soter 52

---

**LEO®** is a trademark mentioned below to the LEO Group.

**Further information can be found in the Summary of Product Characteristics or Leaflet.**

**Further information can be found in the Summary of Product Characteristics or Leaflet.**

**Further information can be found in the Summary of Product Characteristics or Leaflet.**

---

**Adverse events should be reported. Reporting forms and information can be found at:**

www.mhra.gov.uk/yellowcard

**Further information can be found in the Summary of Product Characteristics or Leaflet.**

**Further information can be found in the Summary of Product Characteristics or Leaflet.**

**Further information can be found in the Summary of Product Characteristics or Leaflet.**

---

**Legal category:**

POM.

---

**Drug interactions:**

Interactions with systemically absorbed medicinal products for malignancy should be biopsied to determine appropriate treatment.

---

**Precautions and warnings:**

Avoid contact with eyes. If accidental exposure occurs,

---

**Legal category:**

POM.

---

**Drug interactions:**

Interactions with systemically absorbed medicinal products for malignancy should be biopsied to determine appropriate treatment.

---

**Precautions and warnings:**

Avoid contact with eyes. If accidental exposure occurs,

---

**Legal category:**

POM.

---

**Drug interactions:**

Interactions with systemically absorbed medicinal products for malignancy should be biopsied to determine appropriate treatment.

---

**Precautions and warnings:**

Avoid contact with eyes. If accidental exposure occurs,
Organising Committee

- Miss Sally-Ann Koomson – Marketing & Events Coordinator
- Mrs Marie Elwér – Finance and Conference Officer
- Miss Danielle Bailey – Events Coordinator

Conference & Event Services

- Mr Chris Garrett - Conference & Event Services Manager
- Mrs Jenna Bowler – Senior Events Coordinator
- Mrs Marie Elwér – Finance and Conference Officer
- Miss Sally-Ann Koomson – Marketing & Events Coordinator
- Mrs Danielle Bailey – Events Coordinator

Bad Judging Committee

- Dr Michael Arden-Jones
- Dr David Eddy
- Prof Eugene Healy
- Dr Eduardo Calonje
- Dr Paul Craig
- Dr Lynne Jamieson
- Dr Jane McClelland
- Dr Catherine Orteu
- Prof Malcolm Rustin - Chair
- Dr Graham Sharpe
- Dr Graeme Stables
- Dr Saleem Talibee

Bad Abstract Selection Committee

- Dr Helen Home
- Dr Sarah Wakelin
- Dr Mark Wilkinson

BSPD Abstract Selection Committee

- Dr Susannah Baron
- Dr Fiona Browne
- Dr Jane Ravenscroft
- Dr Hossain Shahidullah

BSD Abstract Selection Committee

- Dr Eduardo Calonje
- Dr Paul Craig
- Dr Lynne Jamieson
- Dr Saleem Talibee

BSDS Abstract Selection Committee

- Dr Colin Fleming
- Dr Vindy Ghura
- Dr David Harris
- Dr Raj Mallipadde
- Dr Graeme Stables

BSSCH Abstract Selection Committee

- Dr Catherine Harwood
- Dr John Lear
- Dr David Page
- Dr Bill Phillips
- Prof Charlotte Proby
- Dr Helen Ramray

BTS Abstract Selection Committee

- Dr Carolyn Charman
- Dr Saul Halpern
- Dr Colin Morton

Historical Abstract Selection

- Dr Peter Copeman
- Dr David Eddy
- Dr Julia Ellis
- Dr Frances Humphreys
- Dr Nick Leveill
- Dr Sid Orgin
- Dr Benok Patalay
- Dr Paul Yesudian

Acknowledgements

The British Association of Dermatologists gratefully acknowledges the contribution of the many exhibitors & sponsors whose attendance has helped make the meeting possible.

A Warm Welcome to Liverpool 2013

Welcome to Liverpool for the 93rd Annual meeting of the British Association of Dermatologists. Thank you for registering, we hope you have an enjoyable meeting. Once again we are in the award winning Liverpool Arena and Convention Centre, located in the world-famous Liverpool waterfront. Liverpool is a diverse and exciting city with a huge range of attractions, hotels and restaurants in close proximity to the conference centre. Situated in the heart of the city on the historic, world-heritage waterfront, the Liverpool Arena and Convention Centre is a state-of-the-art conference venue offering all the space, facilities and professional service to satisfy the needs of our delegates and exhibitors, making it the ideal location to stage a successful Annual Meeting.

Scientific Programme

The annual meeting committee has again worked hard to provide a blend of new scientific presentations with updates from experts in various fields. We are pleased to announce that the Arthur Rook Oration will be delivered by Professor Richard Gallo from San Diego, USA. Professor Chris Denton from London will give the first of the guest lectures at the plenary session on Tuesday speaking on Sclerodermia. He will be followed later that afternoon by Professor Wendy Reid, Medical Director of HEE, who will talk about ‘Health Education England - the new structure for education and training in the NHS’. Wednesday’s programme features Professor Irwin McLean who will update the BAD membership on inherited skin barrier defects in atopic eczema. The final guest lecture will come from Professor Nicolas Soter, Professor at New York University School of Medicine, who will talk during the CPD session on Thursday afternoon on ‘A Current Therapeutic Armamentarium for Chronic Idiopathic and Autoimmune Urticaria/Angioedema’.

For those who did not attend the International Investigative Dermatology meeting in Edinburgh we have asked the authors of the top scoring abstracts from UK training dermatologists to present their data at the Professors and registrars forum.

On Monday 8th July we will be holding pre-conference sessions for trainees, Specialty & Associate Specialist doctors, medical students and there will be a BSD self assessment session.

We will have a new session on Wednesday morning titled ‘Understanding Pharma’. All the Satellite Symposia will take place on Wednesday, with the focus sessions on Thursday lunchtime, featuring topics on Genital Dermatology, Dermoscopy and Clinical Services Issues.

Medical Dermatology features strongly in the programme with a dedicated session on Wednesday afternoon. Professors Brian Kirby, Lesley Rhodes and Frank Nestle will be presenting at the Professors and Registrars plenary forum on Thursday morning, with the popular CPD session taking place in the Thursday afternoon slot.

Social Programme

The Welcome Reception will be held at the ACC Liverpool venue, offering a chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. The reception will be situated in the Galleria beginning after the final session finishes at 18:00 and will leave time for attendees to dine afterwards.

The Annual Dinner will be held in St George’s Hall in the centre of the city. St Georges Hall is widely regarded as one of the finest neo-classical buildings in the world and will provide a magnificent venue for the event.

We hope you have a great meeting, please do not forget the on-line evaluation survey, your views and feedback are crucial to planning of future meetings. Thank you to all our speakers, exhibitors and delegates for all adding to the anticipated success of the meeting.

Enjoy!

Malcolm Rustin
Academic Vice President (2011-2013)
DELEGATE INFORMATION A – Z

ACCOMPANYING PERSONS
We regret that neither accompanying persons nor children/ babies are permitted entrance to the exhibition areas, sessions or social events.

APP
We are pleased to announce that we will be providing a smartphone conference app for delegates to use during the conference.

The app will provide the following features;
• Real time polling during sessions
• Ask the speaker a question
• Take notes on sessions
• Provide session feedback
• Full agenda details
• Speaker profiles
• Social Media
• Sponsor and exhibitor listings

Now is a great time to get the conference app on your mobile device. To access the app simply open your Smartphone browser and enter the following URL: www.bad2013app.org or scan this QR Code.

BADGES
Conference badges will be handed to delegates on registration. For security purposes name badges must be worn at all times throughout the meeting. In the event that you lose your badge, a replacement must be obtained at the registration desk immediately.

BANKING
A Barclays cash machine is situated on site, on the riverside of the building. Walk down the steps before the exit and the machine is on the left; there is no charge for using it.

BUSINESS SERVICES
The E.On Business Centre offers various services, including photocopying, faxing, workstation hire, courier services and sale of stationery and various Liverpool souvenirs.

CATERING
Lunch and all scheduled refreshment breaks will be served from designated points in the exhibition area, Hall 2 of the ACC. If the nearest catering point is not open, staff will direct you to the next most convenient point.

CERTIFICATES OF ATTENDANCE
Certificates of attendance will be in your registration envelope.

CLOAKROOM
There is a cloakroom located on either side of the Galleria. There is a charge of £1 per item. Guests will also be able to store luggage on the day of departure.

COMMITTEE MEETINGS
A programme of the scheduled committee meetings can be found on page 11.

DEVELOPMENT CREDITS (CPD)
This event will be approved for External credit for the CPD Scheme of the Federation of Royal Colleges of Physicians of the UK. Physicians should record their credits in their diaries, in accordance with the current RCP recommendations. Participants should only record the number of hours they attended. The main meeting has been approved for 18 credits and the CPD code is 80200.

EXHIBITION
The exhibition will be located in Hall 2 of the ACC and will be open at the following times:

Partner 9th July 10:00 – 17:30
Wednesday 10th July 08:30 – 17:30
Thursday 11th July 08:30 – 15:30

EXHIBITION QUIZ
Exhibition quiz forms will be included in delegate bags. To participate in the quiz, delegates must visit each participating exhibitor and answer a simple question. Participants must also obtain 4 answers from the patient support groups, please note you only need 4 from any of the Patient Support Groups present over the duration of the meeting. All completed quiz forms must be returned to the registration desk by 14:00 on Thursday 11th July. The prizes will be announced after the meeting.

EXHIBITORS
Please see page 62 for a full list of exhibitors and an exhibition plan.

FIRST AID
The stewards at the venue will be able to assist you.

FOCUS SESSIONS
All 13:15 – 14:00 Free of charge, but do not include a sandwich bag.

Thursday 11th July
• Genital Dermatology
• Dermoscopy
• Clinical Services Issues

MESSAGES
A delegate notice board will be situated adjacent to the registration desk, where all delegates’ messages will be displayed.

PARKING
The nearest car park to ACC Liverpool is the 1,600 multi-storey car park which is on site.

The 1600 space multi-storey Liverpool Waterfront Car Park is fully secure and open 24 hours a day, 7 days a week. It is centrally located on Kings Dock at the site of the ACC Liverpool.

PATIENT SUPPORT GROUPS
The following patient support groups will be represented at the meeting and will have stands in the Hall 2:

Tuesday 9th July & Wednesday 10th July
Caring Matters Now
Ehlers Danlos UK
Golin Syndrome Group
Skin Camouflage Network
Xeroderma Pigmentosum Support Group

Wednesday 10th July
Psoriasis & Pсорiatric Arthritis Alliance

Wednesday 10th July & Thursday 11th July
Behcits Syndrome Society
Lates Allergy Support Group

Thursday 9th July, Wednesday 10th July, Thursday 11th July

Alopecia UK
British Association of Skin Camouflage
Changing Faces
Ichthyosis Support Group
Nodular Prumo International
SKIN
The Hyperhidrosis Support Group
The Pioriasis Association
UK Dermatology Clinical Trials Network
Vitiligo Society
Worldwide Lichen Sclerosus

Thursday 11th July
Skincare Cymru

In addition, the following groups will have stands within the exhibition:

BADBIR
BAD Communications
British Skin Foundation
BAD journals
Clinical Services Unit
Community Dermatology & IFD
Historical Collection
2014 World Congress on Cancers of the Skin
Special Interest Groups

PAYMENT OF REGISTRATION FEES
We would prefer delegates to pay by cheque (payable to the ‘British Association of Dermatologists’. Cheques in other currencies cannot be accepted. Alternatively, delegates may pay by credit card and this is encouraged for overseas delegates. Please note that we only accept MasterCard and Visa. American Express cannot be accepted.

POSTER EXHIBITION
The poster exhibition will be located within the exhibition hall. The posters will be numbered and a list is provided on pages 53-57.

There will be an e-poster display area showing all the posters submitted. Posters should not be removed until 14:00 on Thursday 11th July. Please note that the British Association of Dermatologists cannot be held responsible for any loss or damage to a poster presented during the Annual Meeting.

REGISTRATION DESK
The registration desk will be located on the Galleria level and will be staffed by the BAD team during the following hours:

Monday 8th July 09:30 – 18:00
Tuesday 9th - Thursday 11th July 08:00 – 18:00

RESTAURANTS
For further information about local restaurants and bars around Liverpool please visit www.visitliverpool.com

The ACC Liverpool Delegate Card will be made available to every delegate attending the conference and is packed with offers, discounts and privileges across a range of bars, restaurants, hotels and attractions throughout Liverpool.

SATellite SYMposia
The following companies will be holding satellite symposia at the meeting:

Wednesday 10th July
08:00 – 08:45 Hall 3A Almirall
08:00 – 08:45 Hall 3B Beiersdorf
13:15 – 14:15 Hall 1A & B Meda
13:15 – 14:15 Hall 3A AbbVie
13:15 – 14:15 Hall 3B Janssen
18:15 – 19:00 Hall 3A Novartis
18:15 – 19:00 Hall 3B Leo Pharma
**VENUE**

ACC Liverpool,
Kings Dock,
Liverpool Waterfront, L3 4FP

For Sat Nav, please use the postcode L3 4BX

T: +44 (0)151 475 8888
Email: info@accliverpool.com
www.accliverpool.com

**Wi-fi**

There is wi-fi access throughout the ACC. Please search WiFi hotspots on your device and select free WiFi. You will then be automatically connected.

---

**SPEAKER PREVIEW**

Speaker preview will be located in Hall 6 & 7 on the upper level at the ACC, please ask at the registration desk for directions. All presenters must take their memory sticks to speaker preview at least two hours prior to their presentation. Data projection (PowerPoint) will be available.

**SPECIAL INTEREST GROUPS**

The following Special Interest Groups will hold their meetings during the week of the conference. All special interest group meetings will take place in Liverpool. Their full programmes are featured at the back of each days full programme.

**Tues 9th July**

- British Society for Skin Care in Immunocompromised Individuals
  09:00 – 11:40 (Page 23 - 24)
- British Teledermatology Society
  10:00 – 11:50 (page 25)
- British Society for Cutaneous Allergy
  09:15 – 12:35 (Page 26 - 27)
- British Society for Paediatric Dermatology
  09:00 – 12:30 (Page 28 - 30)
- Historical
  11:00 – 12:30 (Page 31 - 32)
- British Society for Dermatopathology
  15:00 – 18:00 (Page 33 - 35)

**Wednesday 10th July**

- British Society for Dermatological Surgery
  14:00 – 17:10 (Page 42 - 45)
- British Photodermatology Group
  14:30 – 17:45 (Page 46-47)

**TAXIS**

Black Cabs are often parked outside the ACC. The phone numbers of local taxi firms are: Davy Liver 0151 708 7080, Delta 0151 924 7373 and Village Cabs 0151 427 7909.

---

**TRANSPORT – IN AND AROUND Liverpool – TO AND FROM ACC Liverpool**

[http://www.btconventioncentre.com/coming/find_us](http://www.btconventioncentre.com/coming/find_us)

**By Road**

For all car journeys it’s best to follow the white on brown tourist route signs for the Waterfront. These signs are visible on the major routes into the city. ACC Liverpool is situated on the Kings Dock directly adjacent to the south side of the Albert Dock. Upon arrival, the Kings Dock entrance is clearly sign posted.

**From the North**

Leave the M6 at junction 26 and follow signs for M58 Liverpool. Follow to end of M58 and then take signs for A59 Liverpool. Continue to follow Liverpool City Centre until picking up signs for the Waterfront. The 1600 space multi-storey Liverpool Waterfront Car Park is signposted ‘Waterfront’ on the city wide ‘available spaces’ signage.

**From the South**

Leave the M6 at junction 21A and take the M62 to Liverpool. At the end of the M62 follow signs for Liverpool City Centre along Edge Lane, picking up and following signs for Waterfront. The 1600 space multi-storey Liverpool Waterfront Car Park is signposted ‘Waterfront’ on the city wide ‘available spaces’ signage.

**By Air**

Liverpool John Lennon Airport is just 8 miles from the city centre, and a 20 minute taxi ride to the ACC, with regular flights to Ireland and Europe. A taxi from the airport to the city centre will take approximately 20 minutes or the express bus service Route 500 will take approximately 25 minutes, dropping you off within a five minute walk of ACC Liverpool.

**By Rail**

Liverpool is easily accessible by train from many other major towns and cities across the country, and can be reached in a journey time of just over two hours form London. ACC Liverpool is a 20-minute walk from Lime Street or a short taxi ride.

---

**Wi-fi**

There is wi-fi access throughout the ACC. Please search WiFi hotspots on your device and select free WiFi. You will then be automatically connected.

---

**DELEGATE INFORMATION A – Z**

---

**Social Events**

Please see Social Programme (Page 10).

---

**Transport**

http://www.btconventioncentre.com/coming/find_us

**Key**

- Lift
- Escalator
- Stairs
- Male/Female Toilets
- Disabled Toilets

---

**DELEGATE INFORMATION A – Z**
SOCIAL EVENTS

WELCOME RECEPTION
ACC Liverpool
Tuesday 9th July 18:00 – 20:00
The Welcome Reception will be held at the ACC Liverpool venue. Offering a unique chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. Drinks and canapes will be served after the final session finishes at 18:00 and will leave time for attendees to dine afterwards.

The reception will take place on the Galleria, the spine connecting the arena and convention centre.

ANNUAL DINNER
St George’s Hall
Wednesday 10th July, 19:30
The Annual Dinner will be held in St George’s Hall in the centre of the city. St George’s Hall is widely regarded as one of the finest neo-classical buildings in the world and will provide a magnificent venue for the event.

COMMITTEE MEETINGS

MON 8TH JULY:

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 13:00</td>
<td>SAS Sub-committee</td>
<td>Hall 5</td>
</tr>
<tr>
<td>16:00 – 18:00</td>
<td>British Association of Dermatologists Officers</td>
<td>Hall 5</td>
</tr>
<tr>
<td>18:30 – 19:30</td>
<td>National Dermatology Trainee Committee</td>
<td>Hall 4B</td>
</tr>
</tbody>
</table>

TUES 9TH JULY:

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:00</td>
<td>British Society for Dermatopathology Exec Committee</td>
<td>Hall 14</td>
</tr>
<tr>
<td>08:00 – 09:00</td>
<td>British Society for Paediatric Dermatology Training Committee</td>
<td>Hall 13</td>
</tr>
<tr>
<td>08:30 – 10:30</td>
<td>British Skin Foundation Grants Advisory</td>
<td>Hall 9</td>
</tr>
<tr>
<td>08:45 – 09:15</td>
<td>The British Society for Cutaneous Allergy (BSCA) AGM</td>
<td>Hall 1C</td>
</tr>
<tr>
<td>10:30 – 12:30</td>
<td>Dermatology Industry Group</td>
<td>Hall 11C</td>
</tr>
<tr>
<td>11:30 – 13:00</td>
<td>British Skin Foundation Trustees</td>
<td>Hall 13</td>
</tr>
<tr>
<td>11:40 – 12:10</td>
<td>British Society for Skin Care in Immunocompromised Individuals AGM</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>12:00 – 14:00</td>
<td>Community Dermatology Editorial Board</td>
<td>Hall 8</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td>Senior Skin Group</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>13:30 – 14:30</td>
<td>Historical Collection Sub-Committee</td>
<td>Hall 9</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>Teachers of Undergraduate Dermatology</td>
<td>Hall 13</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>Health Informatics Sub-committee</td>
<td>Hall 5</td>
</tr>
<tr>
<td>14:00 – 17:00</td>
<td>British Society for Cutaneous Allergy Committee</td>
<td>Hall 12</td>
</tr>
<tr>
<td>14:30 – 15:00</td>
<td>British Society for Dermatopathology AGM</td>
<td>Hall 1C</td>
</tr>
<tr>
<td>16:00 – 17:00</td>
<td>Therapy &amp; Guidelines Sub-committee</td>
<td>Hall 13</td>
</tr>
<tr>
<td>17:00 – 18:00</td>
<td>British Society for Paediatric Dermatology Committee</td>
<td>Hall 5</td>
</tr>
<tr>
<td>17:30 – 18:30</td>
<td>UK DCTN Trial Prioritisation Panel</td>
<td>Hall 9</td>
</tr>
<tr>
<td>17:30 – 18:30</td>
<td>BAD Session Judging Committee</td>
<td>Hall 14</td>
</tr>
</tbody>
</table>

WED 10TH JULY:

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:00</td>
<td>Skin Cancer Prevention Sub-committee meeting</td>
<td>Hall 8</td>
</tr>
<tr>
<td>08:00 – 09:00</td>
<td>BJD Editorial Board Meeting</td>
<td>Hall 13</td>
</tr>
<tr>
<td>08:30 – 10:30</td>
<td>British Society for Medical Dermatology Committee</td>
<td>Hall 9</td>
</tr>
<tr>
<td>09:00 – 10:30</td>
<td>UKDCTN AGM/Steering Group</td>
<td>Hall 14</td>
</tr>
<tr>
<td>11:00 – 13:00</td>
<td>British Association of Dermatologists’ AGM (Members Only)</td>
<td>Hall 1A</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>PUVA Guidelines Meeting</td>
<td>Hall 14</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>British Association of Dermatologists Officers</td>
<td>Hall 5</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>British Cosmetic Dermatology Group AGM</td>
<td>Hall 13</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td>British Photodermatology Group Committee</td>
<td>Hall 8</td>
</tr>
<tr>
<td>13:15 – 14:15</td>
<td>Dermatology Forum for Wales Phototherapy sub-committee</td>
<td>Hall 4B</td>
</tr>
<tr>
<td>14:30 – 15:30</td>
<td>British Association of Dermatologists’ Executive Committee</td>
<td>Hall 4A</td>
</tr>
<tr>
<td>14:30 – 18:00</td>
<td>BAD Session Judging Committee</td>
<td>Hall 14</td>
</tr>
<tr>
<td>17:30 – 18:00</td>
<td>UK Professors Group</td>
<td>Hall 8</td>
</tr>
<tr>
<td>17:10 – 17:45</td>
<td>British Society for Dermatological Surgery AGM</td>
<td>Hall 1C</td>
</tr>
<tr>
<td>17:45 – 18:15</td>
<td>British Photodermatology Group AGM</td>
<td>Hall 12</td>
</tr>
</tbody>
</table>

THURS 11TH JULY:

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 09:30</td>
<td>Exhibitors’ Meeting</td>
<td>Hall 13</td>
</tr>
<tr>
<td>09:00 – 12:00</td>
<td>British Society for Dermatological Surgery Committee</td>
<td>Hall 14</td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td>Specialised Dermatology Clinical Reference Group</td>
<td>Hall 13</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>BAD Session Judging Committee</td>
<td>Hall 14</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td>World Congress on cancers of the Skin 2014 Programme Committee</td>
<td>Hall 13</td>
</tr>
<tr>
<td>14:30 – 15:30</td>
<td>World Congress on cancers of the Skin 2014 LOC</td>
<td>Hall 13</td>
</tr>
</tbody>
</table>
ADDITIONAL MEETINGS

TUES 9TH JULY:

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 14:30</td>
<td>Senior Skin Group</td>
<td>Hall 3A</td>
</tr>
<tr>
<td></td>
<td>For further information please contact <a href="mailto:maggie@kirkup.plus.com">maggie@kirkup.plus.com</a></td>
<td></td>
</tr>
<tr>
<td>16:30 – 17:30</td>
<td>Dermatology Teachers</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>16:30</td>
<td>Barriers and bridges: integrating dermatology learning into undergraduate programmes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers: Dr Charlotte Reddick, Dr Lily Wheeler and Dr Mini Singh</td>
<td></td>
</tr>
<tr>
<td>16:55</td>
<td>How to make the most of the new BAD smartphone App for medical students</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr James Coleman and Dr Ingrid Helbling</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>Education update: what’s been happening?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr Stuart Cohen</td>
<td></td>
</tr>
</tbody>
</table>

THURS 11TH JULY:

<table>
<thead>
<tr>
<th>TIME</th>
<th>MEETING</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 – 08:30</td>
<td>Christian Medical Fellowship</td>
<td>Hall 4B</td>
</tr>
<tr>
<td></td>
<td>If you would like to reserve a place at the breakfast please visit the on site registration desk.</td>
<td></td>
</tr>
</tbody>
</table>

Bringing together the best of the private and NHS worlds

Premium specialist reporting services by a team of 10 dermatopathologists, all holding substantive NHS positions / 24-48 hours turnaround / Competitive flat fee structure for up to 7 specimens (including courier, special stains, immunocytochemistry and billing) / Second opinion from expert panel / Reports delivered securely by email and via SSL-encrypted website / Frozen sections & MDM support / Privileged access to educational material.

Dr Florence Deroide, MD - Partner
Consultant Dermatopathologist and Head of the Cellular Pathology Department at the Royal Free Hospital. Trained in France (Paris Ouest, Angers), more than 13 years of experience, including 10 in the UK. Florence co-organises the Anglo-French dermatopathology meeting in London and is a reviewer for Journal of Plastic, Reconstructive & Aesthetic Surgery.

BAD 93rd Annual Meeting
(9th - 11th July)
Meet our team on STAND 41

Dr Alistair Robson BSc (Hons) - Partner
FRCPath DipRCPath
Consultant Dermatopathologist for 12 years at the tertiary referral centre St John’s Institute of Dermatology. Speaker at international conferences in the US, Middle & Far East and member of the Unna Darier Dermatopathology Society. Numerous research works presented in the last 12 months at top international forums, e.g. American Academy of Dermatopathology, British Society of Dermatopathology, World Lymphoma Congress in Berlin...

Join the 100+ clinicians already benefiting from our first class services

Office +44 20 8090 5802 (8am-6pm) | Mob +44 7817295534 | operations@ldpath.com | www.ldpath.com
PROGRAMME INDEX

MONDAY
Overview 15
Dermatopathology Self Assessment 16
Trainee pre-conference session 17
SAS Session 18

TUESDAY
Overview 19
Clinico-pathological cases - Joint BAD / BSD 20 - 21
Plenary 21 - 22
British Society for Skin Care in Immunocompromised Individuals 23 - 24
British Teledermatology Society 25
British Society for Cutaneous Allergy 26 - 27
British Society for Paediatric Dermatology 28 - 30
Historical 31 - 32
British Society for Dermatopathology 33 - 35

WEDNESDAY
Overview 37
Plenary 38
Understanding Pharma 39
Medical Dermatology Plenary Session 40
BAD and BDNG Joint Meeting 41
British Society for Dermatological Surgery 42 - 45
British Photodermatology Group 46 - 47

THURSDAY
Overview 49
Professor’s & Registrars’ Forum 50 - 51
Focus Session 51
CPD Session 52

Additional meetings 12
Bristol Cup posters 33 - 57
MONDAY 8TH JULY – DERMATOPATHOLOGY SELF ASSESSMENT PROGRAMME

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td></td>
<td>Registration at ACC Liverpool (2 minute walk from Jurys Inn Hotel)</td>
<td>JURYS INN HOTEL</td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td>Presentation of cases 1 - 20</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td>Tea and Coffee and further opportunity to register</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td>Presentation of cases 21 - 40</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td>End of session</td>
<td></td>
</tr>
</tbody>
</table>

Approved by Royal College of Pathologists for CPD centre purposes to a maximum of 4 credits

Speakers:
- Eduardo Calonje
- Richard Carr
- Rino Cerio
- Martin Cook
- Paul Craig
- Sara Edward
- Lynne Jamieson
- Wolter Mooi
- Ed Rytina
- Maureen Walsh

MONDAY 8TH JULY – TRAINEE PROGRAMME

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td></td>
<td>Welcome Lunch</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>12:55</td>
<td></td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Shaheen Haque-Hussain and Dr David de Berker</td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>TPC01</td>
<td>Photodermatology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Tsui Ling</td>
<td></td>
</tr>
<tr>
<td>13.40</td>
<td>TPC02</td>
<td>Biologics in psoriasis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof Catherine Smith</td>
<td></td>
</tr>
<tr>
<td>14.20</td>
<td>TPC03</td>
<td>Connective tissue disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Simon Megitt</td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td>TPC04</td>
<td>Lasers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Vishal Madan</td>
<td></td>
</tr>
<tr>
<td>15.40</td>
<td>TPC05</td>
<td>Update on trainee issues</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Shaheen Haque-Hussain</td>
<td></td>
</tr>
<tr>
<td>15.45</td>
<td></td>
<td>Tea / Coffee</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>16.00</td>
<td>TPC06</td>
<td>Ehrlers-Danlos syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Nigel Burrows</td>
<td></td>
</tr>
<tr>
<td>16.40</td>
<td>TPC07</td>
<td>Psychodermatology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Tony Bewley</td>
<td></td>
</tr>
<tr>
<td>17.20</td>
<td>TPC08</td>
<td>How to write a business case?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tania von Hospenthal</td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td>TPC09</td>
<td>Quiz</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr David de Berker</td>
<td></td>
</tr>
<tr>
<td>18.20</td>
<td>TPC10</td>
<td>Final remarks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Shaheen Haque-Hussain and Dr David de Berker</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>Close</td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td>Trainee &amp; Dermschool evening event</td>
<td>Blue Bar</td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td>End of session</td>
<td></td>
</tr>
</tbody>
</table>

Approved by Royal College of Pathologists for CPD centre purposes to a maximum of 4 credits
MONDAY 8TH JULY – SAS PROGRAMME

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td></td>
<td><strong>Registration and lunch</strong></td>
<td>Hall 4B</td>
</tr>
<tr>
<td>13.00</td>
<td>SAS01</td>
<td><strong>Welcome and Introduction</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Glenda Hill</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CHAIR:</strong> Dr Inma Marie-Sole</td>
<td></td>
</tr>
<tr>
<td>13.05</td>
<td>SAS02</td>
<td><strong>Occupational dermatitis and the role of patch testing</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Mark Wilkinson</td>
<td></td>
</tr>
<tr>
<td>13.45</td>
<td>SAS03</td>
<td><strong>Difficult and unusual vulval conditions – how I manage them</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Hazel Bell and Mr John Kirwan</td>
<td></td>
</tr>
<tr>
<td>14.25</td>
<td>SAS04</td>
<td><strong>Using immunoglobulin therapies in dermatology</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof Carrock Sewell</td>
<td></td>
</tr>
<tr>
<td>15.05</td>
<td></td>
<td><strong>Tea / Coffee</strong></td>
<td>Hall 4B</td>
</tr>
<tr>
<td>15.35</td>
<td>SAS05</td>
<td><strong>Systemic treatment for severe adult atopic dermatitis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof Nick Reynolds</td>
<td></td>
</tr>
<tr>
<td>16.15</td>
<td>SAS06</td>
<td><strong>Cutaneous drug reactions – a brief overview and an update on identification of culprit drugs</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Michael Ardern-Jones</td>
<td></td>
</tr>
<tr>
<td>16.55</td>
<td></td>
<td><strong>Amyloidosis – an overview and guidance for dermatologists on when referral for further investigation is appropriate</strong></td>
<td></td>
</tr>
<tr>
<td>17.35</td>
<td></td>
<td><strong>Closing remarks</strong></td>
<td></td>
</tr>
<tr>
<td>19.30</td>
<td></td>
<td><strong>SAS evening event</strong></td>
<td>Gusto Restaurant</td>
</tr>
</tbody>
</table>

TUESDAY 9TH JULY – OVERVIEW
<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 18:00</td>
<td></td>
<td>Registration desk open</td>
<td>Galleria</td>
</tr>
<tr>
<td>09:15 – 12:30</td>
<td></td>
<td>BRITISH SOCIETY FOR CUTANEOUS ALLERGY (PAGE 26 – 27)</td>
<td>HALL 1C</td>
</tr>
<tr>
<td>09:00 – 12:30</td>
<td></td>
<td>BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY (PAGE 28 – 30)</td>
<td>HALL 11A &amp; B</td>
</tr>
<tr>
<td>09:00 – 11:40</td>
<td></td>
<td>BRITISH SOCIETY FOR SKIN CARE IN IMMUNOCOMPROMISED INDIVIDUALS (PAGE 23 – 24)</td>
<td>HALL 3B</td>
</tr>
<tr>
<td>10:00 – 11:50</td>
<td></td>
<td>BRITISH TELEDERMATOLOGY SOCIETY (PAGE 25)</td>
<td>HALL 4B</td>
</tr>
<tr>
<td>09:30 – 10:26</td>
<td></td>
<td>CLINICOPATHOLOGICAL CASES</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joint meeting with the British Society of Dermatopathology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIRS: Dr Eduardo Calonje and Dr Paul Craig</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>CPC-1</td>
<td>Cutaneous cytomegalovirus infection in a patient with generalized pustular psoriasis: a case report</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Green, F. Ali, E. McMullen, M. Judge and L. Motta</td>
<td></td>
</tr>
<tr>
<td>09:37</td>
<td>CPC-2</td>
<td>Trichodysplasia spinulosa</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Rashidghamat, E. Calonje, Anissa Moktefi, Laurence Brudy and Agnès Carlotti</td>
<td></td>
</tr>
<tr>
<td>09:44</td>
<td>CPC-3</td>
<td>Cutaneous Epstein-Barr virus-associated smooth muscle tumours in the immunosuppressed</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R.N. Matin, P. Harden, J.C. Bowling and K. Hollowood</td>
<td></td>
</tr>
<tr>
<td>09:51</td>
<td>CPC-4</td>
<td>Expanding the spectrum of Proteus syndrome: bilateral cerebriiform plantar collagenomas and varicose veins secondary to a mosaic AKT1 mutation</td>
<td>Hall 1A</td>
</tr>
<tr>
<td>09:58</td>
<td>CPC-5</td>
<td>Disseminated malignancy in a patient with Gorlin syndrome: a rare case of metastatic basal cell carcinoma</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Felton, B. Green, Lynne Jamieson and J.T. Lear</td>
<td></td>
</tr>
<tr>
<td>10:05</td>
<td>CPC-6</td>
<td>An evolving birth mark: bilateral segmental neurofibromatosis</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Worsnop, S. Mansour and J. Natkunarajah</td>
<td></td>
</tr>
<tr>
<td>10:12</td>
<td>CPC-7</td>
<td>A mild form of Herlitzian junctional epidermolysis bullosa with recurrent digital necrosis</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Khan, F. Browne, P. Dopping-Hepenstal, L. Ozomena, J.A. McGrath and C. Moss</td>
<td></td>
</tr>
<tr>
<td>10:19</td>
<td>CPC-8</td>
<td>Generalized eruptive keratoacanthoma of Grzybowski</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Haddadseer, K. Hussein, E. Calonje and S. August</td>
<td></td>
</tr>
<tr>
<td>10:26 – 11:14</td>
<td></td>
<td>Coffee &amp; Exhibition</td>
<td>Hall 2</td>
</tr>
<tr>
<td>11:00 – 12:30</td>
<td></td>
<td>HISTORICAL COLLECTION SYMPOSIUM (PAGE 31 – 32)</td>
<td>HALL 3A</td>
</tr>
<tr>
<td>11:14 – 12:45</td>
<td></td>
<td>CLINICOPATHOLOGICAL CASES CONTINUED</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIRS: Dr Lynne Jamieson and Dr Maureen Walsh</td>
<td></td>
</tr>
<tr>
<td>11:14</td>
<td>CPC-9</td>
<td>A case of acantholytic dermatosis localized to the male genitalia</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M.C. Wilmer, C. Perrett, J. Calonje, J. Weir and C. Bunker</td>
<td></td>
</tr>
<tr>
<td>11:21</td>
<td></td>
<td>Reversal of canities in an elderly white woman</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Ranasinghe, E. Rytina and T.K.K. Ha</td>
<td></td>
</tr>
<tr>
<td>11:28</td>
<td></td>
<td>Perineural invasion in primary and recurrent cutaneous squamous cell carcinoma presenting as cranial nerve palsies and pain</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Pratsou, W. Szczecinska, J.R. Manden and I. Ahmed</td>
<td></td>
</tr>
<tr>
<td>11:35</td>
<td></td>
<td>Paraneoplastic palmar fasciitis and polyarthritis syndrome</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Ding and H. Malhomme</td>
<td></td>
</tr>
<tr>
<td>11:42</td>
<td></td>
<td>Anti-small ubiquitin-like modifier activating enzyme positive dermatomysotis</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Latapa, E. Benton, B. Martin and R.W. Groves</td>
<td></td>
</tr>
<tr>
<td>11:49</td>
<td></td>
<td>Oral bishosphonate in the treatment of synovitis, acne, pustulosis, hyperostosis and osteitis syndrome</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Worsnop, B. Ho and J. Natkunarajah</td>
<td></td>
</tr>
<tr>
<td>11:56</td>
<td></td>
<td>ACGP / TEN overlap syndrome: A reaction not to be underestimated</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Worsnop, L. Ostlere and J. Natkunarajah</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td>Joint BAD/BSD Neil Smith Lecture</td>
<td>Hall 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lentiginous melanoma: emerging entity or misnomer?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Professor Wolter Mooi (Amsterdam, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>12:45 – 14:30</td>
<td></td>
<td>Lunch &amp; Exhibition</td>
<td>Hall 2</td>
</tr>
<tr>
<td>15:00 – 18:00</td>
<td></td>
<td>BRITISH SOCIETY FOR DERMATOPATHOLOGY (PAGE 33 – 35)</td>
<td>HALL 1C</td>
</tr>
<tr>
<td>14:15 – 18:00</td>
<td></td>
<td>SCIENTIFIC SESSION - SUBMITTED PAPERS</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIRS: Prof Christopher Bunker and Prof Malcolm Rustin</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td></td>
<td>Official Opening &amp; Welcome – Prof Christopher Bunker</td>
<td>Hall 1A</td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td>A tour of the new BAD Dermatology Smartphone App for medical students</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Ingrid Helbling and Dr James Coleman</td>
<td>Hall 1A</td>
</tr>
<tr>
<td>14:45</td>
<td>O-1</td>
<td>Somatic mosaicism for activating mutations in codon 61 of NRAS is responsible for multiple congenital melanocytic naevi and neurocutaneous melanosis, and underpins the increased risk of melanoma</td>
<td>Hall 1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V. Knöjer, A. Thomas, M. Ishida, N. Bulstrode, P. Stanier, E. Healy, N. Sebire and G. Moore</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td>Clinical characteristics and outcome in multibacillary leprosy patients treated with 12 months World Health Organization multidrug therapy multibacillary regimen: a retrospective analysis of 730 patients from India</td>
<td>Hall 1A</td>
</tr>
</tbody>
</table>

**TUESDAY 9TH JUNE – DETAILED PROGRAMME**
**TUESDAY 9TH JULY – BRITISH SOCIETY FOR SKIN CARE IN IMMUNOCOMPROMISED INDIVIDUALS**

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>BI01</td>
<td>Male genital dermatoses in immunocompromised patients</td>
<td>Hall 1</td>
</tr>
<tr>
<td>09:05</td>
<td>BI02</td>
<td>Developing a standardised actinic keratosis assessment protocol</td>
<td>Hall 2</td>
</tr>
<tr>
<td>09:15</td>
<td>BI03</td>
<td>Response rates of different clinical subtypes of chronic mucocutaneous graft versus host disease to extracorporeal photopheresis</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>09:25</td>
<td>BI04</td>
<td>Prospective study of the incidence of skin cancer in renal transplant patients</td>
<td>Hall 1</td>
</tr>
<tr>
<td>09:35</td>
<td>BI05</td>
<td>Prevalence and associated risk factors for actinic keratoses and actinic field change among renal transplant patients</td>
<td>Hall 2</td>
</tr>
<tr>
<td>09:45</td>
<td>BI06</td>
<td>Impact of skin cancers and premalignancies on the quality of life of organ transplant recipients</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>10:05</td>
<td>BI07</td>
<td>Guest Lecture</td>
<td>Hall 3B</td>
</tr>
<tr>
<td>11:00</td>
<td>BI08</td>
<td>Guest Lecture</td>
<td>Hall 1</td>
</tr>
<tr>
<td>11:10</td>
<td>BI09</td>
<td>Interactive Case Discussion with Expert panel</td>
<td>Hall 2</td>
</tr>
<tr>
<td>11:15</td>
<td>BI10</td>
<td>Male genital dermatoses in immunocompromised patients</td>
<td>Hall 1</td>
</tr>
<tr>
<td>11:20</td>
<td>BI11</td>
<td>Too much hair, not enough hair and acne after a kidney transplant: It’s not always the drugs</td>
<td>Hall 2</td>
</tr>
<tr>
<td>11:25</td>
<td>BI12</td>
<td>A rare case of diffuse cutaneous leishmaniasis in an immunocompromised patient on methotrexate</td>
<td>Hall 1</td>
</tr>
<tr>
<td>11:30</td>
<td>BI13</td>
<td>Bullous pemphigoid mimicking toxic epidermal necrolysis in a HIV infected woman</td>
<td>Hall 2</td>
</tr>
</tbody>
</table>

**CHAIRS:** Dr Catherine Hanwood and Dr Bill Phillips

---

**Translating scleroderma – pathogenesis to targeted therapy**
Professor Christopher Denton (London, UK)

Scleroderma (also termed systemic sclerosis) has the highest mortality of any autoimmune rheumatic disease with more than half of diagnosed patients ultimately dying as a direct result of the disease. However outcomes and survival have improved over the past decade due to systemic investigation, better therapies for organ-based complications. There are now licensed therapies for pulmonary hypertension and digital ulcer disease and an emerging evidence base supporting use of immunosuppression for skin and lung fibrosis. At the same time there is improved understanding of the nature of the pathology, if not its triggering or initiating factors. This lecture will review recent clinical progress in scleroderma, consider how the hallmark pathological processes might be targeted therapeutically. Pathogenesis involves interplay of vascular, immunological and fibrotic pathologies. Gaining understanding of the similarities with other autoimmune diseases as well as better definition of the pivotal mediators or cell types that are important in connective tissue repair and fibrosis is providing impetus for more targeted approaches to treatment being developed. In addition, treatments that have been shown to be effective for other medical conditions such as gastro-oesophageal reflex or pulmonary arterial hypertension are being adapted and used in scleroderma. Thus, a pattern of translation of therapies within the clinical arena is emerging that complements the application of growing understanding of the disease biology that may facilitate new treatment targets or modalities. Finally, there are emerging data suggesting that intensive immunosuppression with autologous stem cell rescue might offer a durable treatment effect albeit with substantial treatment-related mortality. Whether more targeted or specific strategies targeting key pathways or mediators could achieve similar benefit with less toxicity will be considered in this presentation. There has been real progress in a “hard” disease and more can be expected if ongoing clinical trials fulfil their potential.
TUESDAY 9TH JULY – BSSCI PROGRAMME

11:35  B115  Chronic herpes simplex infection in immunocompromised individuals, a diagnostic dilemma
M. Paul, J. Hague, S. Orpin and H. Al-Rawi

11:40  AGM

12:10  Meeting Close

POSTERS

B112  The stubborn skin nodules of Mycobacterium chelonae
S. Tso, H. Recica, J. Brockley and J. Berth-Jones

B113  Pattern of mucocutaneous manifestations in adult patients of leukaemia: cross-sectional prevalence study in 193 adult patients with leukaemia from a tertiary care centre in India
S. Dogra, S. Agrawal, P. Mathota and U. N. Saikia

B114  Evaluation of a nurse-led clinic for skin cancer awareness and surveillance of organ transplant recipients
L. Mitchell, A. Gulati, J.M. McGregor, C.M. Proby and C.A. Harwood

B116  Hailey cell leukaemia presenting as cutaneous interstitial granulomatous dermatitis
N. Arjun, L.H. Lee, G. Soosaipillai, D. McCormick and B. Hughes

B117  Haematological disorders and cutaneous malignancy: do they go hand in hand?
C. Wootton, A. Patel and F. Lawton

B118  An unusual black nodule in a renal transplant recipient

B119  Nonmelanoma skin cancer in HIV positive patients
M. Rajpopat, A. Sahota and S. Rajpopat

B120  Mycobacterium chelonae infection in an immunosuppressed patient presenting in an isolated upper extremity sporotrichoid distribution: a challenging diagnosis
F. Latheef and M. Shah

B121  ‘A Dermatology Smear Campaign’
A. Devine, P. Yesudian and K.S. Chen

B122  Patients presenting to Dermatology with an AIDS-defining illness - a report of three cases
V. Scott-Lang, M. Darling, S.A. Holme, M. Rahilly and S. Allan

B123  Multi-drug resistant Mycobacterium marinum infection in an immunocompromised patient
P. Carrero, S. Z. Jaulim, C. Kasparis, T. Gee and J. Carter

B124  TB or not TB? Pre-biologic screening in a low-medium prevalence population
S. George, C. DeGiovanni, K. Ibrahim, C. Giles, P. Cadogan, E. Alexander and S. Dollman

B125  A case of male breast cancer in a renal transplant recipient
S. Ogden and E. Stewart

B127  Flexural psoriasis triggered by natalizumab for the treatment of multiple sclerosis: a very rare but reported association
F. Latheef and B.P. Walker

B128  An unusual complication of systemic therapy in a patient with atopic eczema
S. Ogden and E. Stewart

B129  Is skin biopsy needed in cases of high clinical suspicion of cutaneous graft versus host disease?
V. Bakunov, N. Aldoori and D.J. Gawkrodger

B130  Calciphylaxis in a patient after 16 years of renal transplant
M. Fadhil and S. Shah

---

TUESDAY 9TH JULY – BRITISH TELEDERMATOLOGY SOCIETY

TIME  CODE PROGRAMME  ROOM

10:00  Welcome Introduction
Dr Saul Halpern

10:10  Guest Lecture
Change in costs and efficiency after a decade of teledermatology: results based on 90,000 teleconsultations
Dr Job van der Heijden (Manager Research and Development, KSYOS Telemedical Centre, Amsterdam)

Teledermatology has been successfully implemented in The Netherlands resulting in improved care trajectories and lower associated costs:

2,816 general practitioners and 203 dermatologists performed teledermatology. 79,361 teleconsultations performed from 2006 to 2012 were included. In the group of patients where the general practitioner sent a teleconsultation to prevent a referral, 73% of physical referrals was prevented. In the group of patients where the general practitioner sent a teleconsultation for a second opinion, 15% were physically referred after teleconsultation. Conventional Care constituted 192,00 per dermatology patient. TeleDermatology constituted 68,00 per teleconsultation. Average price of patient that has been selected for TD: 157,06. The estimated cost reduction was 18%.

What were the factors leading to this success and are they generalizable to other countries, e.g. the UK.

10:30  BT01  Quality measures in a teledermatology service
T. Wing and D.A.R. de Berker

10:50  BT02  Teledermatology service in Tayside, Scotland: a snapshot
Y.N. Lau and C.J. Fleming

11:10  BT03  A new model of teledermoscopy combining service and education
E.Y. Wong, B. Brant, F. Hussain and F.M. Muller

11:30  BT04  Mobile medical technology software applications for dermatologists and their patients
T. Lewis

11:50  AGM
TUESDAY 9TH JULY – BRITISH SOCIETY FOR CUTANEOUS ALLERGY

TIME  | CODE  | PROGRAMME | ROOM
--- | --- | --- | ---
08:45 - 09:15 | AGM | | Hall 1C

09:15 – 12:35 | BRITISH SOCIETY FOR CUTANEOUS ALLERGY | HALL 1C

CHAIRS: Dr Helen Horne and Dr David Orton

09:15  CD01  Prosser - White Oration
Allergic Contact Dermatitis to isothiazolinones - the emerging story
Prof Jeanne Duus Johansen (Gentofte Hospital, Denmark)

09:45  CD02  methylchloroisothiazolinone and methylisothiazolinone contact allergy: a new epidemic
R. Urwin and S.M. Wilkinson

09:55  CD03  Occupational disease in beauticians reported to The Health and Occupation Research network from 1996 to 2011

10:05  CD04  Our experience with alitretinoin in the management of patients with chronic, severe hand eczema
J. Dua, N. Gallacher, K. Warburton and S. Cooper

10:25  CD05  An ethnographic insight into the psychological impact of hand eczema
A. Bewley, N. Mason, J. Rawlins and S. Walker

10:35  Coffee Break

11:05  CD06  Patch testing to the 26 individual labelled fragrances over a two-year period
J. Mann, J. McFadden, J. White, I. White and P. Banerjee

11:35  CD07  Prevalence of allergy to oxidized limonene and linalool in the U.K.

11:45  CD08  An outbreak of allergic contact dermatitis to citral in beauticians working in a health spa
P. De Mozzi and G.A. Johnston

12:05  CD10  Denture stomatitis resulting from tertiary butylhydroquinone- and methylhydroquinone-induced allergic contact mucositis
N.Y.Z. Chang and D.A. Thompson

12:15  CD11  A case of wheat protein isolate allergy manifesting as anaphylaxis and cosmetic allergy
A. Lloyd-Lavery, S.M. Cooper, G. Ogg and J. Reed

12:25  CD12  Metal allergy and joint replacement: advice in the absence of guidelines
D.J. Gawkrodger

POSTERS

CD13  Allergy at arm’s length: occupational contact dermatitis to carbimazole.
N. Farguharsen and I. Coulson

CD14  Wound dressings: a potential source of acrylate induced allergic contact dermatitis
N.Y.Z. Chang and D.A. Thompson

CD15  A case of systemic contact dermatitis due to intra-articular injection of Depo Medrone (methylprednisolone)
Y. Robson, M. Hughes and N. Stone

CD16  Sensitivity to p-phenylenediamine (PPD): positive relationship of response to PPD on patch testing and cross-reactions with other chemically related allergens
B. Thomas, I. White, J. White, M. McFadden and P. Banerjee

CD17  Audit to assess whether a history of a cosmetic reaction or allergic contact reactions to fragrance mix 1 might be predictive of allergic contact reactions to oxidized linalool 6% and oxidized limonene 3%
C. Holden, T. Alenezi, A. Sultan and D.J. Gawkrodger

TUESDAY 9TH JULY – BSCA PROGRAMME
TUESDAY 9TH JULY – BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY

TIME CODE PROGRAMME ROOM
09:00 PA01 Early-onset eczema and disease severity are the main risk factors for food sensitization at 3 months of age in exclusively breastfed infants

09:10 PA02 Oral azathioprine for the treatment of childhood eczema: safety profile and guidelines for monitoring

09:20 PA03 Predictors of persistent mettclillin-resistant Staphylococcal aureus colonization in paediatric atopic dermatitis
C. Foley, R. Cumney, S. Gleson, P. Lenane and B. O'Donnell

09:30 PA04 Risk factors for the onset and persistence of childhood eczema: birth cohort study

09:40 PA05 Interleukin-10 receptor mutation presenting with severe nappy ulceration and infantile inflammatory bowel disease
B.S. McDonald, S. Narayanan, M. Elavad and K. Batta

09:46 PA06 Problematic spitzoid lesions in childhood

09:56 Guest Lecture
Next generation diagnostics for inherited skin disease
Prof John McGrath (London, UK)

Advances in DNA sequencing methods have changed how we diagnose genodermatoses in 2013. New techniques such as whole exome sequencing now permit screening of all the coding regions of the genome in one go to find pathogenic mutations. Moreover, sequencing platforms are becoming cheaper and quicker and more accessible to dermatologists. This lecture will provide examples of how next generation sequencing is being used to diagnose inherited skin diseases and how current generation clinicians can access and benefit from the new DNA sequencing technologies.

10:30 Coffee and posters

CHAIRS: Dr Mary Glover and Dr Susannah Baron

11:00 PA07 Efficacy of topical timolol 0.5% ophthalmic solution to treat infantile haemangioma: a study of 105 haemangiomas from a single centre
D. Khanna and P. Chaikraavarty

11:10 PA08 An audit of the initiation of oral propranolol to treat infantile haemangioma in 35 patients
N. Farquharson, P. Arkwright and T. Clayton

CHAIRS: Dr Olivia Schofield and Dr Hossain Shahidullah

11:20 PA09 Unusual granulomatous skin manifestations in children with primary immunodeficiency
S. Venkatesh, A. Taylor and S. Leech

11:26 PA10 Rituximab in childhood pemphigus: an experience of five patients
A.J. Kanwar and K. Vinay

11:36 PA11 A review of the treatment and demographics of children in the U.K. with vitiligo
A. Scott, N. Dinani and N. Roberts

11:46 PA12 Localized epidermolytic ichthyosis secondary to a novel keratin 1 mutation occurring in monozygotic twins and treated with acitretin
J. Wee, A. Terron-Kwiatkowski, D. Baty, E. O'Toole and J. Natkunarajah

11:52 PA13 Are we harming our children on long-term prescribed oral medications from the effects of sugar and other excipients? A case of tooth decay and review of current guidance
E. Burden-Teh, G. Kemsley and J.C. Ravenscroft

12:00 POSTERS

PA14 Two cases of rapidly invovling congenital haemangiomia
W. Szczecinski and H. Shahidullah

PA15 LEOPARD syndrome or Noonan syndrome? A difficult distinction in early childhood
S. Madhoogaat, S. Sharif and C. Moss

PA16 Vascular Ehlers-Danlos syndrome presenting with abnormal recurrent bruising in a 3-year-old girl
J. Newmam, G.J. Soby and T.H. Clayton

PA17 A difficult case of atopic eczema: useful learning points
M.S. Shroff, L. Alborna, M.J. Cork and S.M. Clark

PA18 Cutaneous xanthomas in homozygous familial hypercholesterolaemia: an important lesson
N.Y.Z. Chiang, C. Agwu, S. Vijay, P. Abdullah and M. Maheshwari
### TUESDAY 9TH JULY – HISTORICAL

#### TIME  CODE PROGRAMME  ROOM

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:30</td>
<td>H01</td>
<td>Thomas Bateman through the looking glass: a newly discovered personal archive of a sensitive man</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L. Millard</td>
</tr>
<tr>
<td>11:15</td>
<td>H02</td>
<td>Dermatology back in the day: a review of inpatient care in the 1940s</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V. Scott-Lang, E.T. Ooi and C. Benton</td>
</tr>
<tr>
<td>11:30</td>
<td>H03</td>
<td>The life and times of the mighty mite</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J.E. Davies and P.D. Yeusidan</td>
</tr>
<tr>
<td>11:45</td>
<td>H04</td>
<td>The story of Daniel Carrion: a fatal quest for insight into oroya fever and verruga disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L. McNulty-Brown and A.V. Anstey</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Guest Lecture</td>
</tr>
<tr>
<td></td>
<td></td>
<td>King George III’s madness; the porphyria myth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof Timothy Peters (Birmingham, UK)</td>
</tr>
</tbody>
</table>

**Recent re-evaluation of the King’s medical records has shown that Macalpine & Hunter were highly selective in their reporting omitting any evidence that did not support a diagnosis of porphyria, and indicates that the King suffered from recurrent attacks of acute mania, i.e., bipolar disorder.**

The reasons for and consequences of Hunter and Macalpine’s misleading claim will be discussed.

### POSTERS

<table>
<thead>
<tr>
<th>Code</th>
<th>Poster</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA20</td>
<td>A tale of two brothers: neonatal lupus in an antibody-negative family</td>
</tr>
<tr>
<td></td>
<td>A. Khoo and E.P. Burova</td>
</tr>
<tr>
<td>PA21</td>
<td>Ichthyosis prematurity syndrome in two siblings</td>
</tr>
<tr>
<td></td>
<td>M. Farquharson, S. Sivashankar and I.H. Coulsen</td>
</tr>
<tr>
<td>PA22</td>
<td>Deep infantile haemangioma responding to propranolol after the proliferative stage</td>
</tr>
<tr>
<td></td>
<td>E. Burden-Teh and R. Murphy</td>
</tr>
<tr>
<td>PA23</td>
<td>Lichen planopilaris: the paradoxical role of tumour necrosis factor antagonists</td>
</tr>
<tr>
<td></td>
<td>M. Walsh, P. Jayasekera and R.A.G. Parslew</td>
</tr>
<tr>
<td>PA24</td>
<td>Phenotypic and genotypic overlap between acro-dermato-ungual-lacrimal-tooth syndrome and ectrodactyly-ectodermal dysplasia-clefting syndrome: a better classification is needed</td>
</tr>
<tr>
<td></td>
<td>S. Madhu, L. Ozoemena, J.A. McGrath and C. Moss</td>
</tr>
<tr>
<td>PA25</td>
<td>A leukemic congenital leukemia cutis</td>
</tr>
<tr>
<td></td>
<td>S. Ayob, J. Payne, M. Al-Adrani and S. Garg</td>
</tr>
<tr>
<td>PA26</td>
<td>Aneurysmal fibrous histiocytoma in a 3-year-old child</td>
</tr>
<tr>
<td></td>
<td>L. Rahimi, L. Hook, E. Bytina, I. Grant, C. Fischer and J. Gass</td>
</tr>
<tr>
<td>PA27</td>
<td>Dermatitis simula ta and the art student</td>
</tr>
<tr>
<td></td>
<td>H. Bridgestock and H. Recica</td>
</tr>
<tr>
<td>PA28</td>
<td>Poliosis noma of Cerecizuo</td>
</tr>
<tr>
<td></td>
<td>A. Kaps and M.S. Shareef and S.M. Clark</td>
</tr>
<tr>
<td>PA29</td>
<td>Buschke-Ollendorff syndrome affecting lower limb function in two children</td>
</tr>
<tr>
<td></td>
<td>C. Goodhead, C. Blasdale and A. Taylor</td>
</tr>
<tr>
<td>PA30</td>
<td>Beckwith-Wiedemann syndrome with multifocal infantile haemangiomas and hepatic haemangioendotheliomas</td>
</tr>
<tr>
<td></td>
<td>L. Craven and A. Belga</td>
</tr>
<tr>
<td>PA31</td>
<td>A case of juvenile xanthogranuloma with bilateral retinal detachment</td>
</tr>
<tr>
<td></td>
<td>C. Koon, A. Kapadia, W. Merchant and S.M. Clark</td>
</tr>
<tr>
<td>PA32</td>
<td>Orofacial granulomatosis predating the onset of multiple autoimmune diseases: an autoimmune association?</td>
</tr>
<tr>
<td></td>
<td>N.Y.Z. Chiang and A. Abdullah</td>
</tr>
<tr>
<td>PA33</td>
<td>Localized congenital giant juvenile xanthogranulomas resolving with atrophic sequelae</td>
</tr>
<tr>
<td></td>
<td>S. Saw, K. Batta and A. Rubin</td>
</tr>
<tr>
<td>PA34</td>
<td>Spinal dysraphism and its cutaneous signs</td>
</tr>
<tr>
<td></td>
<td>M. Paul, A. Loffeld, H. Goodyear and D. Rodrigues</td>
</tr>
<tr>
<td>PA35</td>
<td>A case of congenital tufted angioma: a rare vascular tumour</td>
</tr>
<tr>
<td></td>
<td>S. Rajan and C. Kennedy</td>
</tr>
</tbody>
</table>
**TUESDAY 9TH JULY – HISTORICAL**

**Arthur Whitfield, 1868-1947: much more than an ointment**  
*A. Sharma*, W. Malein and S. Orpin

**‘Wigging out!’**  
*A. Devine* and P.D. Yesudian

**The men behind the lines**  
*F. Worsnop*, B. Ho and J. Natkunarajah

**Historical use of radiation epilation for tinea capitis in childhood: a life sentence?**  
*K. Nago*, P. Jayasekera, R.M. Azurdia and J. Verbov

**The mystery of the Black Sore (Kara Yara)**  
*M. Malik* and P.D. Yesudian

**Francis Xavier Dercum, 1856-1931: a less than dolorous life**  
*M. Crow*, A.H.M. Heagerty and S. Orpin

**On target: erythema multiforme, a history**  
*Z. Venables* and N.J. Level

**Gerhard Henrik Armauer Hansen (1841–1912), the man who unveiled the mystery of leprosy**  
*M. Paul*, Y. Mansouri and A. Loffeld

**What’s in a name? The historical descriptions of hidradenitis suppurativa**  
*R. Coelho* and N.J. Level

**New empires and old enemies: the story of tuberculosis and its cutaneous manifestations**  
*S. Laird*, *P. Gazzani* and C. Kasparis

---

**TUESDAY 9TH JULY – BRITISH SOCIETY FOR DERMATOPATHOLOGY**

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 09:00</td>
<td></td>
<td>Executive BSD Committee Meeting</td>
<td>Hall 14</td>
</tr>
<tr>
<td>09:30 – 12:15</td>
<td></td>
<td>Clinicopathological Cases, Joint meeting with the British Association of Dermatologists</td>
<td>Hall 1A</td>
</tr>
<tr>
<td>12:15 – 12:45</td>
<td></td>
<td>Joint BAD/BSD Neil Smith Lecture</td>
<td>Hall 1A</td>
</tr>
<tr>
<td>14.30 – 15.00</td>
<td></td>
<td>BSD AGM</td>
<td>Hall 1C</td>
</tr>
</tbody>
</table>

**15:00 – 18:00**

**BRITISH SOCIETY FOR DERMATOPATHOLOGY**

**HALL 1C**

**CHAIRS:** Dr Eduardo Calonje and Dr Lynn Jamieson

15:00: Introduction and comment on posters

15:05 DP01: Merkel cell carcinoma in the U.K.: an urgent need for evidence-based management  
*M. Sommerlad*, C.A. Harwood and R. Cerio

15:12 DP02: A 10-year retrospective review of vulval squamous cell carcinoma associated with lichen sclerosus  
*S.H. Hussain*, M. Chattopadhyay, A. Shiraz, G. Meligonis, P. Baldwin and J. Sterling

15:19 DP03: Is granuloma faciale part of the IgG4-related disease spectrum?  
*E. Ieremia*, Agnes Carlotti and E. Calonje

15:26 DP04: p63 and nuclear factor- B expression in primary cutaneous B-cell lymphoma: further evidence for pathogenetic heterogeneity  
*Z. Shukur*, P. Coates, A. Subtil, W. Kempf, D. Sahni and A. Robson

15:33 DP05: Retrospective 20-year review of pathology reporting of eccrine porocarcinoma in a U.K. dermatology unit  

15:40 DP06: A retrospective study of 13 cases of vulvar melanoma  

15:47 DP07: Cutaneous granulomatous lesions in congenital immunodeficiency states  
*C. Fleming*, B. Martin, E. Calonje and C. Smith

15:54 DP08: Perineural inflammation in scleroderma: systematic characterization of a poorly recognized but potentially useful histopathological feature  
*C.A. Dhaliwal*, A.I. MacKenzie and A. Biswas

16:01 DP09: Report of two cases of the so-called ‘malignant’ dermatofibroma: can behaviour be predicted on morphology?  
*W. Rickaby*, *E. Ieremia*, M. del Carmen Gonzalez Vela, J. Fernando Val-Bernal, G. Saldanha and E. Calonje

16:08: Coffee break
Early melanoma. Small melanoma. Naevoid melanoma. How many are melanomas?
Prof Wolter Mooi (Amsterdam, The Netherlands)

Neoplastic transformation and progression to malignancy is a multistep process, but diagnostic tumour pathology strives to categorize individual lesions as either benign or malignant. Only tumors that never behave as cancer are called benign. The problem of this oversimplification is, that groups of lesions that only rarely behave as cancers, need to be labelled as malignant, for truly benign lesions never do. Benignity guarantees no further trouble, malignancy indicates a chance of further trouble, even when that chance is small.

When a very thin melanocytic lesion is diagnosed as melanoma, everyone expects the patient to do well, and no one challenges the pathologist’s diagnosis if the patient does well. However, the situation is entirely different if the pathologist has diagnosed a benign entity, but the lesion subsequently behaves as a cancer. Accordingly, there is a constant pressure on diagnostic pathologists to call a ‘difficult’ lesion malignant. Obviously, one cannot diagnose naevoid in doubt about the possibility of a malignant potential of a lesion. In order to avoid overdiagnosing melanoma on the one hand, and taking risks on the other, I believe it is wise to use a category of melanocytic tumours (or proliferations) of uncertain malignant potential (MELTUMPs).

DP10 17:15  Clinicopathological analysis of 54 patients with cicatricial alopecia
A. Khalid, K.S. Chen and P.D. Yesudian

DP11 17:22  Cryoglobulinaemia: the tip of the rete ridge
K. Muttardi, E. Calonje and B. De Silva

DP12 17:29  Bullous scabies associated with positive direct immunofluorescence
B.S. McDonald, C. Orteu and V. Swale

DP13 17:36  An unusual case of finger ulceration
N. Bansal, A. Imtiaz, S. Taibjee, R. Carr and H. Kutzner

DP14 17:43  Squamous cell carcinoma arising within disseminated superficial actinic porokeratosis
M. Chatterjee, E. Rytina and P.M. Todd

DP15 17:50  The forgotten sign: half-half blisters as a presentation of meticillin-resistant Staphylococcus aureus bullous impetigo in a 20-year-old woman returning from the tropics
J. Dua, A. Gafita, E. Davies, C. Rodriguez-Garcia and S. Grabczynski

DP16 17:57  Best presentation prize and close

POSTERS

DP16 16:30  LYMPHOPLASTIC MACULAR PLAQUE IN CHILDREN: A REPORT OF TWO ADULT CASES
E.T. Ooi, A. Biswas, O. Schofield, V.R. Doherty and C.S. Murray

DP17 16:30  TO COMPARISON BETWEEN BACILLARY INDEX ON SLIT-SKIN SMears WITH GRANULOMA IN PATIENTS WITH LEPROSY: ITS RELEVANCE TO PRESENT THERAPEUTIC REGIMENS
M.F. Kumaran, S. Dogra, T. Narang and U.N. Saikia

DP18 16:30  A REVIEW OF MELANOMA PATHOLOGY REPORTING: LOOKING BEYOND JUST BRESLOW THICKNESS
S. Cheung, L. Ahmed and A. Youssef

DP19 16:30  CHRONIC FIBROSING VASCULITIS OF THE PENIS
S. Nair, C. Murray, V. Swale, E. Calonje and S. Mazzon

DP20 17:00  A RARE VARIANT OF FIBRO SARCOMATOUS DERMATO FIBROSARCOMA PROTUBERANS
P. Falandero, A. D’Souza, E. Calonje and S. Hoque

DP21 17:05  INFliximab-INDUCED ALOPECIA: A RECENTLY DOCUMENTED ANTITUMOUR NECROSIS FACTOR-ADVERSE EVENT AND A NOVEL CAUSE OF NONCICATRICAL ALOPECIA
E. Ieremia, K. Anneke and C. Stefanato

DP22 17:10  MID DERMAL ELOSTASIS OF THE BACK PRESENTING 6 YEARS POST-TOXIC EPIDERMAL NECROSIS
C. Cunningham, L. Joseph and J. Ferguson

DP24 17:15  LEXINPRIL-INDUCED PEMPHIGUS
C. Haddadeen, L. Craven, W. Chong and C. Stephens

DP25 17:20  THINK ZINC: ACQUIRED ACRODERMATITIS ENTERTHOPATHICA IN A PATIENT WITH METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY
V. Salter, S. Ekanayake, M. Malik and M. Petkar

DP26 17:25  CUTANEOUS PERINEURAL GRANULOMATOUS INFLAMMATION MASQUEURADING AS LEPROSY
B. Shaheen, P. Woo and A. Barbieri

DP27 17:30  A WIDESPREAD GRANULOMATOUS Eruption HERALDING THE ONSET OF MYELODYSPLOSTIC SYNDROME
A. Fogo, H. Hunter, D. McLornan and S. Walsh

DP28 17:35  MULTIPLE SCROTAL VERUCIFORM XANTHOMAS IN A WEST AFRICAN MAN
D. O’Callaghan, V. Dvorakova, P. Marren and P. Regan
Kilimanjaro Challenge
London Marathon
Trans Pennine Challenge
Moonriders Cycle Ride
British 10K
Great North Run

Find out how you can help
The British Skin Foundation
4 Fitzroy Square, London W1T 5HQ
www.britishskinfoundation.org.uk
For general enquiries and to make a donation:
0207 391 6341
admin@britishskinfoundation.org.uk
For fundraising and events enquiries:
0207 391 6088
events@britishskinfoundation.org.uk
For press and media enquiries:
0207 391 6347
press@britishskinfoundation.org.uk
09:45 - 10:40  UNDERSTANDING PHARMA  Hall 1A

CHAIRS: Prof Christopher Bunker and Mr Howard May

Skin health – beauty and well-being
Dr Michèle Verschoore, Medical Director, L’Oreal Research & Innovation

To the extent that they help improve our appearance, cosmetics can affect how we relate to ourselves and to others, and as such can improve quality of life. Such benefits may be objectively demonstrated using validated methods and quality-of-life scales.

The aim of this review will be to assess the effects of cosmetics on well-being in various situations based on studies using objective measurement methods. It can be demonstrated that in pathological settings, the use of cosmetics can significantly improve the quality of life and well-being of patients, resulting in better acceptance of their disease and better therapeutic compliance. The use of cosmetics has also shown to exert positive effects on self-esteem and social relations. A growing body of studies demonstrates the beneficial effects of cosmetics on well-being under normal physiological conditions. We can conclude that today, the effects and benefits of cosmetics can be measured objectively using quality-of-life scales, allowing initiation of actions for the recovery of well-being and self-esteem.

Basics of Dermatology Medicines Development
Dr Barbara White, SVP and Head of R&D, Stiefel

Learning Objectives:
1. Understand challenges in creating a significant value proposition for a new medicine in dermatology: creating value for patients, physicians, health agencies, and payers
2. Understand approaches to manage some common risks at different stages in development of medicines for dermatology, including some common challenges in topical formulations
3. Understanding the promise of translational medicine approaches in development of new medicines for dermatology

Quo Vadis, global dermatology
Mr Humberto Antunes, President and CEO, Galderma S.A

The world is changing rapidly. Those interested in dermatology wonder how the world will look and how their practice of medicine will be in 10, 20 or 30 years. The gloomy scenarios from the year 2000 have not taken place for the specialist in dermatology in 2013. In this talk, we will discuss some of the projections for global dermatology and how industry, academia and physicians can work together to improve patient outcomes and to shape a prosperous future for the practice.
14:30 – 16:00

**SCIENTIFIC SESSION – MEDICAL DERMATOLOGY & SUBMITTED PAPERS**

Hall 1A

**MD01**

**14:30**

**Advances in hidradenitis management**

Prof Gregor Jemec (Copenhagen, Denmark)

**O-11**

**Infliximab for hidradenitis suppurativa: should we be measuring antibody levels?**

Z. Lahab, Z. Arkir, E. Agius and N. Desai

**15:15**

**O-12**

**A novel use for botulinum toxin A in the management of ileostomy and urostomy leaks**

V. M. Smith and C.C. Lyon

**15:30**

**MD02**

**Mastocytosis management for the Dermatologist**

Dr Clive Grattan (Norwich, UK)

16:00 – 16:30

Tea & Exhibition

Hall 2

16:30 – 18:00

**Scientific Session – Medical Dermatology & Submitted Papers Continued...**

Hall 1A

**MD03**

**16:30**

**Systemic treatments for the photodermatoses**

Dr Robert Sarkany (London, UK)

Systemic therapy is a mainstay of treatment for the photodermatoses for a variety of reasons. Firstly, some photodermatoses, including Porphyria Cutanea Tarda, Hydroa Vacciniforme and Lupus, are cutaneous manifestations of generalised and systemic diseases, requiring treatment of the underlying systemic disorder. Secondly, some of the Inflammatory Photodermatoses are severe and tend to require treatment with systemic immunosuppressant drugs, particularly severe Chronic Actinic Dermatitis and Actinic Prurigo. Thalidomide is the systemic immunosuppressant of choice in Actinic Prurigo. Finally, we routinely use oral Psoralens as an immunosuppressant activated by UVA, when we give PUVA.

**17:30**

**O13**

**The risk of postoperative complications in patients with psoriasis or psoriatic arthritis on biological therapy**


**17:45**

**O-14**

**Drug survival of fumaric acid esters for psoriasis: a retrospective study**

N. Ismail, B. Kirby, P. Collins and A. Lally

14:45 – 16:45

**JOINT SESSION - BRITISH ASSOCIATION OF DERMATOLOGISTS AND BRITISH DERMATOLOGICAL NURSING GROUP**

Hall 11A & B

**CHAIRS:**

Dr Ferina Ismail and Carrie Wingfield

**14:45**

**JM01**

**Melanoma / targeted therapies**

Dr Louise Fearfield

**15:05**

**JM02**

**Skin Surgery: The Nurse Consultant’s Perspective**

Carrie Wingfield

**15:25**

**JM03**

**Non melanoma skin cancer / pre-cancerous skin conditions**

Dr John Lear

**15:45**

**JM04**

**The development of BDNG Skin Cancer Nursing Competencies**

Saskia Reeken

**16:05**

**JM05**

**Skin cancer surgery / Mohs**

Dr Ed Seaton

**16:25**

**JM06**

**The Nursing Care of Patients on Systemic Medication for Malignant Melanoma**

Rachel Duncan

19:30 – 00:00

Annual Dinner

St George’s Hall

19:30 – 23:00

BSDS Annual Dinner

The Athenaeum
**WEDNESDAY 10TH JULY – BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY**

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 17:10</td>
<td>DS01</td>
<td>Safety, complications and patients’ acceptance of Mohs micrographic surgery under local anaesthesia: results from the U.K. Mohs Acceptance and Patient Safety Collaboration Group</td>
<td>BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY HALL 1C</td>
</tr>
<tr>
<td>14:07</td>
<td>DS02</td>
<td>Abstract withdrawn</td>
<td></td>
</tr>
<tr>
<td>14:14</td>
<td>DS03</td>
<td>Surgical excision vs. imiquimod 5% cream for basal cell carcinoma: a multicentre noninferiority randomized controlled trial</td>
<td></td>
</tr>
<tr>
<td>14:21</td>
<td>DS04</td>
<td>Short duration cold trypsinization as a novel method in noncultured epidermal suspension transplantation in stable vitiligo</td>
<td></td>
</tr>
<tr>
<td>14:28</td>
<td>DS05</td>
<td>Analysis of a dermatopathology audit of Mohs section reporting by Mohs surgeons in a Mohs fellowship training dermatology surgery unit</td>
<td></td>
</tr>
<tr>
<td>14:35</td>
<td>DS06</td>
<td>Change in histological diagnosis following Mohs micrographic surgery</td>
<td></td>
</tr>
<tr>
<td>14:42</td>
<td>DS07</td>
<td>Two-centre audit of Mohs surgery using a U.K. national Mohs minimal dataset: next steps to test the agreed minimum dataset</td>
<td></td>
</tr>
<tr>
<td>14:49</td>
<td>DS08</td>
<td>Five-year experience of the Johnson square procedure for lentigo maligna and lentigo maligna melanoma: the Nottingham experience of 15 cases</td>
<td></td>
</tr>
<tr>
<td>15:03</td>
<td>DS10</td>
<td>Skin adhesive use in cutaneous surgery</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>DS11</td>
<td>Suspension sutures to achieve aesthetically favourable horizontal primary closure of infraorbital Mohs defects to avoid ectropion: a case series of six patients</td>
<td></td>
</tr>
</tbody>
</table>

**15:17** DS12 The Z-plasty pedicle flap for enhanced cosmesis in upper cutaneous lip repair

R. Urwin and W. Hussain

**15:24** DS13 The ‘apical lip flip’ for challenging defects of the nasal ala

R. Urwin and W. Hussain

**15:31 – 16:00** Coffee Break Hall 2

**16:00** CHAIRS: Dr Raj Mallipeddi and Dr Colin Fleming

**15:45** DS14 A prospective study of secondary intention scalp wound healing and outcomes following skin cancer excision

G. Stables, S. Varma

**16:52** DS15 The lenticular island pedicle flap for large centrofacial defects

A. Affleck, C.M. Lawrence and J.A.A. Langtry

**16:59** DS16 The ‘bridge rotation’: a novel repair option for periorcular and peranasal surgical defects

R. Montgomery and W. Hussain

**17:10 – 17:45** BSDS AGM Hall 1C

**POSTERS**

**DS17** Variations in histological subtypes of basal cell carcinoma between initial biopsy and final excision

E. Storan, R. Urwin and W. Hussain

**DS18** Mohs micrographic surgery for desmoplastic trichoepithelioma: a report of 11 cases

S.A. Rice, T.J. Oliphant, C.M. Lawrence and J.A.A. Langtry

**DS19** ‘The spaghetti technique’: a useful technique in the surgical management of lentigo maligna and lentigo maligna melanoma

E. Storan, R. Urwin and W. Mansfield

**DS20** Pilot study of use of ‘photographic rhinometry’ following Mohs micrographic surgery for skin cancers

C.J. Fleming

**DS21** Potential use of patient-reported outcome measures after Mohs surgery

C.J. Fleming

---

**Guest Lecture**

Dermatological Surgery: A view from the other side of the pond

Prof Chris Zachary (Irvine, California, USA)

25 years later, the transformation in British Dermatological Surgery is astounding. In 1987, there was a reluctance on the part of dermatologists in the UK to accept the concept that we should be performing anything but the most menial of surgical procedures. Those of us had surgery fellowship training in the US were considered odd ball, and somewhat inferior and certainly less significant than the ‘complete dermatologist’. Thus started the slow transition, first in Mohs surgery and reconstruction, and then in laser and aesthetic medicine. There is an understanding in the US that dermatologists are more skilled and more economical than some of our other surgical specialists in the removal of skin cancers. And particularly in the field of lasers and devices, dermatological surgeons are preeminent in their development and utilization. This presentation will review some of the latest trends and surgical treatments for skin problems in the USA, and evaluate which side of the Pond is excelling in 2013!
WEDNESDAY 10TH JULY – BSDS PROGRAMME

DS22  The ‘inverted’ advancement and inferior rotation of the nasal sidewall flap for defects of the medial canthus
R. Urwin and W. Hussain

DS23  The specialist nonmelanoma skin cancer multidisciplinary team
M.S. Shareef, W. Hussain, C. Fenn, F. Roberts, W. Merchant and G.J. Stables

DS24  Management of Merkel cell carcinoma in the south east of England: a retrospective cohort analysis of 67 cases over a 7 year period
G. Collart, J. Schofield and S. Collart

DS25  A prospective qualitative study of patient satisfaction following secondary intention wound healing
S. Verykios, K. Aljefri, T.J. Oliphant and J.A.A. Langtry

DS26  Carcinoma cuniculatum on the heel treated pain free with Mohs micrographic surgery using ultrasound-guided sciatic nerve block
A. Patel, N. Bedford and S. Varma

DS27  Trends in incidence of invasive cutaneous squamous cell carcinoma in the north of Scotland over the last 35 years: implications for healthcare spending and the need for increased local sun protection advice
A. Bonsall, E. Semple, E. Hussain and S. Rapsara

DS28  Improving cosmosis at the donor site using discarded skin following an interpolated paramedian forehead flap procedure
M. Rajpopat and N. Sheth

DS29  ‘Skimming the surface’: a review of split-thickness skin grafting practice and preferences among dermatological surgeons in the U.K.
M.S. Shareef and W. Hussain

DS30  The contralateral subgaleal advancement–rotation flap for the single-stage repair of large defects of the lateral forehead and temple
M.S. Shareef and W. Hussain

DS31  The ‘shark-fin’ flap for medium-to-large-sized defects of the preauricular cheek
R. Montgomery and W. Hussain

DS32  Hidradenitis suppurativa: the surgical option
J. Sullivan, N. Kelemen and S. Al-Ghazal

DS33  Cutaneous odontogenous sinus tracts: a clinician’s dilemma
M.S. Kumaran, T. Narang, S. Dogra and S. Bhandari

DS34  Destructive treatment of lymphangioma with carbon dioxide laser and diathermy
C. Duhovic, J. Soo, N. Kuganenderan, P. Mortimer and C.C. Harland

DS35  Immobilization of full-thickness skin grafts using a multilayered polyurethane foam dressing
W.L. Ho, K.E. Eustace, P. Ormond and R. Barry

DS36  Double hatchet flap for reconstruction of lower-limb defects: technique and comparison with type II keystone flap
F. Hussain and F. Muller

DS37  The merits of using alternate staining with toluidine blue and haematoxylin and eosin during Mohs micrographic surgery for basal cell carcinomas
N. Anjum, P. Shepherd and G. Sega-Hall

DS38  Self-funding low-priority benign skin lesion surgery: an evaluation of a new service
S. Anthony, F. Tatnall, K. Batta and K. Mead

DS39  Disparity in skin surgery patient information leaflets: do we need a national template?
W. Hunt and E. McGrath

DS40  Trilobed flap repair for nasal tip and alar defects in eight patients
R.R. Rahim and J.A.A. Langtry

DS41  Use of the Skin Cancer Index to identify preoperative psychological morbidity
A. Affleck, M. Moyes and C.J. Fleming

DS42  Laser resurfacing of facial hypertrophic scarring with an erbium: YAG laser
D. Seukeran

DS43  An extremely delayed reaction following an intradermal filler: a case highlighting the need for tighter regulation and a U.K. register of adverse events related to minimally invasive cosmetic procedures
W. Bakkour and T. Griffiths
WEDNESDAY 10TH JULY – BRITISH PHOTODERMATOLOGY GROUP

TIME          CODE PROGRAMME          ROOM
14:30 – 17:45  BRITISH PHOTODERMATOLOGY GROUP   HALL 12

CHAIRS: Dr Robert Sarkany and Dr Christopher Edwards

BPG 2013 GUEST SPEAKERS

14:30
Modern Photopatch Testing: A product of co-operation between photo and contact dermatology groups
Prof James Ferguson (Dundee, UK)

Photocutaneous dermatitis is a recognised clinical problem which started with the sulphonamides, salicylanilides and antibacterial agents, the Phototoxicity due to topical agents is well described as the photophotodermatitis group due mainly to psoralen chemical and UVA exposure. Photoallergy, as investigated by photopatch testing has a history going back many years. Unfortunately it has long been recognised to be bedevilled by lack of a standardised technique. To a certain extent it has fallen between two subspecialty stools.

This problem needing a solution was recognised jointly by the European Photodermatology Group and the European Society for Contact Dermatitis. Some 13 years ago a joint task force was established by these Groups. Over the following decade a series of “interested expert” workshops produced consensus views of photopatch test methodology, essentially a movement to sort out the chaos of multiple methodologies, variable irradiation techniques and large unwieldy lists of photoallergens complicated by largely obsolete chemicals. The UK took on the lead role and has encouraged the new consensus methodology established by workshops with initially a UK and Dutch study which has been followed by Pan European work with a consensus modernised group of photopatch test chemicals, namely around the sunscreens and topical nonsteroidal anti-inflammatory agents. The appropriate use of this test system, as with photopatch testing, reveals the diagnosis in patients with an unexplained photodamaged site dermatitis.

This joint activity has popularised a standardised methodology throughout Europe. It is expected that patients will now also benefit from a commercially available adapted standard European photopatch test list of agents. It is an agreed view that photoallergy is an underdiagnosed skin condition.

15:05
The Photobiology of Vitamin D
Prof Antony Young (London, UK)

CHAIRS: Dr Robert Dawe and Dr Victoria Goulden

15:40 PD01
Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions
M. Sethi, A. Lehmann, A. Robson, D. McGibbon, R. Sarkany and H. Fassihi

15:55 PD11
MMP12 is induced by UVA1 but not UVB
A. Tewari, K. Grys, R. Sarkany and A. Young

16:10 PD03
Self-administration of hospital-based narrowband UVB (TL-01) phototherapy: a feasibility study in an outpatient setting
S. Yule, S. Sanyal, S. Ibbotson, H. Moseley and R.S. Dawe

16:25 Coffee Break Hall 2

17:00 PD04
Evaluation of patient’s and healthcare professional’s knowledge and views about home phototherapy.
S. Lumley, K. Sobak and Alex Anstey

17:15 PD05
A regional audit of phototherapy services
R. Urwin, D. Turner and V. Goulden

17:30 PD06
An overview of patients investigated in the National Photodiagnostic Service in a tertiary setting over a 22-year period
H. Naasan, R.S. Dawe, H. Moseley and S. Ibbotson

17:45 Close of meeting

17:45 – 18:15 BPG AGM Hall 12

POSTERS

PD07
Determination of optimum operating point for hand held minimum erythema dose device
D. Turner and V. Goulden

PD08
Subcutaneous panniculitis-like cutaneous T-cell lymphoma treated with UVA-1 phototherapy
V. M. Smith, R. Rose and V. Goulden

PD09
An illustrative case series of X-linked dominant protoporphyria
M. Seager, S. Whatley, A.V. Anstey and T. Millard

PD10
Do display monitors and ‘tablet’ screens emit sufficient UVA or UVB to affect photosensitive patients?
A. Patel, E. Burden-Teh, M. Lam, P. Akram, R. Farley and S. Varma

PD12
2011–2012 Audit and survey of phototherapy services in the West Midlands (UK)
J. Powell and M. Kaur
## THURSDAY 11TH JULY – OVERVIEW

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Registration Open</td>
</tr>
<tr>
<td>08:00</td>
<td>Specialised Dermatology Clinical Reference Group</td>
</tr>
<tr>
<td>09:00</td>
<td>Professors &amp; Registrars Forum</td>
</tr>
<tr>
<td>10:00</td>
<td>Breakdown</td>
</tr>
<tr>
<td>11:00</td>
<td>BDNG - Differential Diagnosis BDNG - HIV/Transplant</td>
</tr>
<tr>
<td>12:00</td>
<td>Focus Session: Clinical Services</td>
</tr>
<tr>
<td>13:00</td>
<td>BDNG - Paediatric BDNG - Tropical Diseases BDNG - LFS</td>
</tr>
<tr>
<td>14:00</td>
<td>Focus Session: Genital Dermatology</td>
</tr>
<tr>
<td>15:00</td>
<td>CMF Breakfast</td>
</tr>
<tr>
<td>16:00</td>
<td>Exhibitors Meeting WCCS2014 LOC Sessions</td>
</tr>
<tr>
<td>17:00</td>
<td>BSDS Exec Committee Meeting Session Judges</td>
</tr>
<tr>
<td>18:00</td>
<td>BDNG - Radiotherapy</td>
</tr>
</tbody>
</table>

*NOTES*
### THURSDAY 11TH JULY – DETAILED PROGRAMME

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 18:00</td>
<td></td>
<td>Registration desk open</td>
<td>Galleria</td>
</tr>
<tr>
<td>08:30 – 12:15</td>
<td></td>
<td>PROFESSIONALS &amp; REGISTRARS FORUM</td>
<td>Hall 1A</td>
</tr>
<tr>
<td>08:30 – 10:25</td>
<td>CHAIRS:</td>
<td>Prof Eugene Healy and Prof Nick Reynolds</td>
<td></td>
</tr>
<tr>
<td>08:30 RF01</td>
<td></td>
<td>High-sensitivity C-reactive protein as a marker of psoriasis severity and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>cardiovascular risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Reid, C. Sweeney, A-M. Tobin and B. Kirby</td>
<td></td>
</tr>
<tr>
<td>08:45 RF02</td>
<td></td>
<td>Hypertension is prevalent in psoriasis and should be treated more</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>aggressively</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Carroll, A-M. Tobin and B. Kirby</td>
<td></td>
</tr>
<tr>
<td>09:00 PR01</td>
<td></td>
<td>Psoriasis: a multi-system disorder</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof Brian Kirby (Dublin)</td>
<td></td>
</tr>
<tr>
<td>09:20 RF03</td>
<td></td>
<td>A controlled trial of mindfulness-based stress reduction in psoriasis and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>investigation of telomerase as a biomarker of psychological distress</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>D'Alton and B. Kirby</td>
<td></td>
</tr>
<tr>
<td>09:50 PR02</td>
<td></td>
<td>Influence of sunlight exposure on vitamin D status in the UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof Lesley Rhodes (Manchester)</td>
<td></td>
</tr>
<tr>
<td>10:10 RF05</td>
<td></td>
<td>Gamma-secretase mutations in hidradenitis suppurativa (acne inversa): a</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>new insight into disease pathogenesis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trembath and J.N.W.N. Barker</td>
<td></td>
</tr>
<tr>
<td>10:25 – 11:10</td>
<td></td>
<td>Coffee &amp; Exhibition</td>
<td>Hall 2</td>
</tr>
<tr>
<td>11:10 – 12:15</td>
<td>CHAIRS:</td>
<td>Prof Christopher Bunker and Prof Malcolm Rustin</td>
<td></td>
</tr>
<tr>
<td>11:10 RF06</td>
<td></td>
<td>Cutaneous features of dermatomyositis associated with myositis specific</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>antibodies</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>M.-L. Daly, P. Gordon and J.D. Creamer</td>
<td></td>
</tr>
<tr>
<td>11:25 PR03</td>
<td></td>
<td>Melanoma therapy: The elusive magic bullet</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof Frank Nestle (London)</td>
<td></td>
</tr>
<tr>
<td>11:45 RF07</td>
<td></td>
<td>Filaggrin-null individuals with and without eczema have a higher proportion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>of CD11c positive antigen presenting cells than wild type individuals</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Z.C.I. Venables, C.S. Leitch, N.P. Madarasingha, P.M. Fitch, S.E. Howie,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Schwarze and R.B. Weller</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>CODE</th>
<th>PROGRAMME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 RF08</td>
<td></td>
<td>Herpes zoster vaccine effectiveness against incident herpes zoster and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>post-herpetic neuralgia in an older US population</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.M. Langan, L. Smeeth, D.J. Margolis and S.L. Thomas</td>
<td></td>
</tr>
<tr>
<td>12:15 GL04</td>
<td></td>
<td>Arthur Rook Oration</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guest Lecture – Introduced by Professor Christopher Bunker              Hall 1A</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Understanding skin disease through the perspective of innate immunity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Professor Richard Gallo (San Diego, USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The skin protects itself with barriers to the environment and by detecting</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>danger from the environment. Antimicrobial peptides are a critical element</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>of the defensive barrier, while a variety of pattern recognition receptors</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>such as the Toll-like receptors (TLRs) are key to detecting injury. This</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>presentation will describe these findings and discuss their relevance</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>for clinical dermatology.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lunch &amp; Exhibition</td>
<td>Hall 2</td>
</tr>
</tbody>
</table>

### 13:15 – 14:00 FOCUS SESSION: CLINICAL SERVICES HALL 1C

The Clinical Services Focus session will be hosted by Dr Graham Sharpe, Clinical Vice President and Tania von Hospenthal, Clinical Services Manager with guest speaker Roy Lilley, an established, independent health policy analyst, writer, broadcaster and commentator on health and social issues.

The session will focus on the new commissioning landscape and the many facets of service design, to assist members with meeting these challenges. Commissioning of dermatology services seems increasingly complicated within the new NHS structure, particularly with CCGs stepping into the role of commissioner for acute and community dermatology services. We will outline important aspects to help departments deal with commissioning and improve their own service provision, presenting some of the resources which are currently being developed by the CSU for members.

The CSU would like to draw up a Commissioning FAQ ahead of the session targeting members keys concerns. In order to do this, we be contacting members attending the focus session, in advance of the day.

### 13:15 – 14:00 FOCUS SESSION: DERMOSCOPY HALL 3A

Speakers: Dr Jonathan Bowling and Dr Andrew Affleck
Content: In this 45 minute action packed focus session the speakers will cover:

- Novel dermoscopic features of melanoma in situ
- Tropical dermoscopy - the merits of ex-vivo dermoscopy
- Results of the UK dermoscopy survey
- Dermoscopic pitfalls and pearls

### 13:15 – 14:00 FOCUS SESSION: GENITAL DERMATOLOGY HALL 11A & B

- What are the BSSVD and the BSMGD?
  - Dr Jennifer Yell and Dr William Porter

- The importance of pathology in the diagnosis of genital dermatology
  - Dr Luisa Motta, Consultant Dermatopathologist, Salford

- How best to treat “pelvic” pain
  - Dr Winston F de Mello, Consultant in Pain Medicine, Manchester

- Final minutes: Any questions?
CONTINUING PROFESSIONAL DEVELOPMENT SESSION

Hall 1A

14:30 - 18:00

CHAIRS: Dr Graham Sharpe and Dr Richard Parslew

14:30 CPD01

What's New in Infectious Diseases
Dr Mahreen Ameen (London)

15:00 CPD02

What's New in Contact Dermatitis
Dr Mark Wilkinson (Leeds)

15:30 GLO05

Guest Lecture – Introduced by Prof Christopher Bunker

A Current Therapeutic Armamentarium for Chronic Idiopathic and Autoimmune Urticaria/Angioedema
Professor Nicholas A. Soter (New York, USA)

H1-type antihistamines are the therapy of choice in the management of patients with chronic idiopathic or autoimmune urticaria/angioedema. For patients who have failed to benefit from antihistamines, alternative therapeutic measures may be considered. In double-blind trials, the addition of leukotriene receptor inhibitors, nifedipine, dapsone, or diprydamole to antihistamines achieved beneficial responses. Colchicine, hydroxychloroquine, cyclosporine, moxifloxacin, tacrolimus, methotrexate, high-dose intravenous immunoglobulin, plasmapheresis, and narrow-band ultraviolet B phototherapy have been of benefit in clinical trials. Biologic agents were successfully used in a few patients. Thus, additional levels of therapeutic agents are available for the treatment of refractory disease.

16:00 – 16:30 Coffee Break Upper Level

16:30 CPD03

Trends in Dermatological Surgery
Dr Raj Mallipeddi (London)

17:00 CPD04

What's new in General Medicine for Dermatologists
Dr Catherine Orteu (London)

17:30 President’s Address
Professor Christopher Bunker

17:45 Close of meeting

POSTERS

The posters are situated within the Exhibition Hall and there will be a dedicated poster viewing hour on Tuesday July 9th from 13:00 – 14:00. All presenting authors have been asked to stand by their poster at this time. There will also be an e-poster display area within the Exhibition Hall.

BRISTOL CUP POSTERS

Clinicopathological Cases

P01 A case of diffuse dermal angiomatosis related to a breast implant
C. Kwok, M. Shareef, S. Edward and M. Wilkinson

P02 Metastatic basal cell carcinoma
N. Salmon, L.A. Fearfield, M. Gore and J. Larkin

P03 Animal-type melanoma: how should we manage this rare entity?
C. Sinclair, T. Allan, I. Navroz and S. Fraser

P04 Three generations of hereditary leiomyomatosis associated with renal cell cancer
Z. Versailles, A. Ramaya, S. Holden and G.W.M. Millington

P05 Dermatoses localizing to radiotherapy sites
R. Hellen, C. Kiely, A. Murad, P. Lenane, F.J. Moloney and N. Mulligan

P06 Churg–Strauss presenting with urticated skin lesions
N. Salmon and L.A. Fearfield

P07 Female-pattern hair loss in a hypopituitarism: possible response to androgen replacement therapy
A. Jamil and A. Messenger

P08 Dösserker tuberous xeroyedema revisited: a rare variant of scleromyxedema
S. R. Ali, P. Ho, I.H. Chaudhry, L. Motta and R.J.G. Chalmers

P09 Urticarial vasculitis associated with an acquired reactive perforating collagenosis in pregnancy
S. Worsnop, S. Enyamaga, J. Wee, B. Ho and J. Natkunarajah

P10 de Toni–Fanconi syndrome secondary to fumaric acid esters
C. Reid, J. Holian, D. Kane and B. Kirby

P11 First case report of localized bullous pemphigoid occurring on an oedematous leg secondary to chronic superficial femoral artery occlusion
I. Dua, E. Davies, A. Gaffia, C. Rodriguez-Garcia and S.A. Grabcynska

P12 The psychological impact of a diagnosis of basal cell carcinoma
S. Noel, D. Dunn and R. Wilson

P13 Toxic epidermal necrolysis-like lupus
N. Sprenger, L. Frolkes and V. Alkraa

P14 Erythema multiforme caused by ingestion of atropine eye drops: a previously unreported phenomenon
F. Latheef, R. El-Naes and R.M. Strauss

P15 Primary cutaneous cryptococcosis in a patient with chronic lymphocytic leukaemia treated with alemtuzumab
E. Storan, W. Ho, M. McMenamin and B. Wynne

P16 Biological switching: infliximab- and adalimumab-induced folliculitis
S. Worsnop, K. Misich and J. Natkunarajah

P17 Fluocinolone-induced unusual drug reaction in a child: an example of epitope spread
M. Chattopadhyay, S. Haque-Hussain, E. Rytina and T.K.K. Ha

P18 Leukaemia cutis mimicking pyoderma gangrenosum
Y. Mansouri, T.T. Lew and J.M.R. Goulding
POSTERS

P19 Atypical hidradenitis suppurativa involving nonfl exural body sites
A. Affleck and H. Nasnan

P20 Multiple exquisitely painful leg ulcerations in a teenager
L. Brockley, H. Recica, S. Tso and A. Ilchyshyn

P21 Lupus erythematosus and inclusion body myositis: an important association
B. Green, L. Motta, R.G. Cooper and R.B. Warren

P22 Papuloverruciforma of Oufji: case report and review of the literature
Y. Mansouri, B. Stranks, P. Collody, E. Todd and M.R. Kaur

P23 Novel mutation in keratin 10 causing autosomal dominant epidermolytic ichthyosis
B. Lamb, A. Terron-Kwiatkowski, J. Lang, I. McLean and M. Zamiri

P24 Langerhans cell histiocytosis: treatment of cutaneous disease with azathioprine
A. Rao and A. Chu

P25 Multiple halo naevi associated with tocilizumab treatment
K.H. Kuet and M.J.D. Goodfield

P26 Acute necrotizing eosinophilic myocarditis: a rare complication of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms syndrome. A case report
C. Mitchell, W.A. Woo and J. Hextall

P27 Identification of a novel mutation causing Bloom Syndrome with no facial telangiectasia or erythema
L. Powell, N. Cooper and F. Browne

P28 Vemurafenib-exacerbated eruptive disseminated syringomas
C. Haddadeen, C. Morgan, K. Hussein, R. Osborne and A. Belgi

P29 Autonomic leuconychia
L. Newell and D.A.R. de Berker

P30 X-linked recessive dyskeratosis congenita: an important dermatological diagnosis
L. Powell, C. Moss, I. Dokal, R. Carr and J. Hextall

P31 Clouston syndrome caused by a heterozygous mutation in connexin 30, resembling pachyonychia congenita
G. Hade, N. Wilson, F. Smith and M. Zamiri

P32 Multicentric reticulohistiocytosis treated with adalimumab
S. Verma, N. Ralph and P. Collins

Education, Training, Service, Audit

P33 An audit of acne treatment referrals at a district general hospital
B. Shaheen and C. Soon

P34 Dermatology on call service: is it really necessary?
N. Anjum, L.H. Lee, A. Haworth and B. Hughes

P35 The U.K. Dermatology Clinical Trials Network Trainee Group: developing evidence-based practice and research engagement among dermatology trainees

P36 Is dermatology a forgotten subject within core medical training?
N. Anjum, L.H. Lee, A. Haworth and B. Hughes

P37 An audit to support the need for emergency dermatology training
V. Pinder, F. Worsnop, J. Wee and L. Ostlere

P38 Addressing a lack of dressings knowledge
C. Wootten and P. Whitehead

N. Sprenger, F. Worsnop, R.A. Marsden and V. Akhras

P40 Dermatology training in the U.K.: does it reflect the diversity of our population?
A. Salam and O.E. Dadzie

General Dermatology

P41 Infections in the ustekinumab psoriasis clinical trial programme: final report with up to 5 years of follow-up
B. Striker, P.D. Gislain, M. Lebwohl and P. Szapary

P42 Utility of a national hair microscopy service
I. Frend, D.A.R. de Berker

P43 The revised Leeds acne grading scale: how accurate and clinically useful is it?
F. Latheef, A. Eady, R. El-Naes and A. Layton

P44 Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms syndrome. A case report
F. Latheef, M. Kertel, G. Krueger and D. Amato

P45 Malignancies in the ustekinumab psoriasis clinical development programme: final report with up to 5 years of follow-up
K. Papp, K. Gordon, V. Ho and P. Szapary

P46 Psychological impact of delusional infestation: preliminary results
B. Shah and A.P. Bevelley

P47 Practical experience of biological treatment of very severe psoriasis: a retrospective case–cohort study of patients with a baseline Psoriasis Area Severity Index score greater than 20
N. Ponsambeth, M. Kalavala, A.V. Anstey, V. Piguet and J.R. Ingram

P48 One person’s pink is another person’s purple
B. Ellis, D. Chew and N. Rajan

P49 Differences in psoriasis severity and exposure to immunomodulatory therapies between cigarette smokers and nonsmokers: observations from the Psoriasis Longitudinal Assessment and Registry in patients with moderate to severe psoriasis
J. Walsh, F. Kertel, G. Krueger and D. Amato

P50 Red scrotum syndrome: a clinicopathological study
T. Narang, S. Dogra, M.S. Kumar and U.N. Saikia

P51 A clinical audit of the effect of targeted advice and vitamin D supplementation on serum vitamin D levels in patients with melanoma
S. Field, J. Davies, A. Mitra, H. Peach, D. Dewar and J.A. Newton-Bishop

P52 Psoriasis, comorbidities and lifestyle: what is the patient’s understanding of it?
S.H. Foo, G. Stewart, T. Mitchell and E. Ladoyanni

P53 Do dermatologists really know the costs of the investigations they request? A survey of dermatologists in practice
F. Latheef and M. Shah

P54 Fatigue as a symptom in psoriasis and psoriatic arthritis
M. Saeder, R. Fitzgerald, P. Collins, S.C.F. Rogers, O. FitzGerald, B. Kirby and A. Tobin

P55 Patch testing practice in the U.K.
B.S. McDonald and D.A. Buckley

P56 How are patients with actinic keratoses managed in primary care?
S. Sanyal, A. Holme and D. Kemmett
Skin Cancer

P57 Five-year recurrence rate of lentigo maligna after treatment with imiquimod determined using in vivo confocal microscopy
A. Keeg, T. Richardson, A. Coleman, R. Mallipeddi and E. Craythorne

P58 Incidence of primary cutaneous T-cell lymphoma in Wales
R. Abbott, S. Dojcinov, C. Kasparis and B. Gee

P59 Progress towards integrating a melanoma diagnostic index into a U.K. dermatology department quality dashboard
P. Gazzard, J. Rothwell, C. Kasparis and B. Gee

P60 The treatment of cutaneous metastatic melanoma with topical diphencyprone
N. Spierings and V. Akhras

P61 The perils of using national cancer surveys to reflect local departmental practices
N. Anjum, C. Coley and A.E. Haworth

P62 Abstract withdrawn

P63 The management of narrowly excised cutaneous squamous cell carcinomas
D. Jain, S. Verykiou, M. Vatve and S. Wahie

P64 Electronic patient booking and quality measures in skin cancer management
C. Fremlin, A.P.J.J. Bray and D.A.R. de Berker

P65 Two-week waits, adherence to referral guidelines, and rate of secondary malignancy in the suspected cancer clinic
E.E. Merika and L.A. Fearfield

Therapy

P66 Iontophoresis for hyperhidrosis: effectiveness of treatment
C. Sharpe, J.K. Schofield and N.C. Hepburn

P67 Predictors of response to increasing the dose of etanercept: results of an audit
K. Alefs, P.J. Hampton and N.J. Reynolds

P68 Audit of potent topical steroid use among new psoriasis patients referred to a dermatology department
C. Reid, K.E. Eustace, C. Keating, R. Hughes, S. Verma, R.B.M. Barry, P. Collins, A. Lally and B. Kirby

P69 Topical immunotherapy with diphencyclcopropenone for alopecia areata: our experience
N.Y.Z. Chiang and A. Abdullah

P70 Delusional infestation and patient adherence to treatment
A. Ahmed and A.P. Bewley

P71 Review of the use of diphencyprone in the treatment of alopecia areata: the last 20 years in Glasgow
B.C. Lamb and S.C. Holmes

P72 Pro forma improves compliance with NICE guidance in the assessment and management of atopic eczema in children under 12 years
K. Scharrer, K. Radley, K. Hussain, N.C. Hepburn and J.K. Schofield

P73 Xeomin® vs. Botox® in the treatment of severe axillary hyperhidrosis
T. T. Lew, A. Francis, M. De Vos, N. Baksh and R. Morris-Jones

P74 Use of botulinum toxin injections to treat nalgalgia paraesthetica
L. Collins, S. Kamath and J.R. Hughes

P75 Inflammatory leg ulcers: do not forget compression
N. Clayton, C.L. Lowney and R.H. Bull

P76 Tuberculosis screening of patients on biological therapies: linking clinical practice to national guidelines

P77 Cardiovascular safety in the ustekinumab Clinical Development Programme: final update with up to 5 years of follow-up
K. Reisch, M. Lebwohl, C.E.M. Griffiths and P. Szpary

P78 Targeted cognitive behavioural therapy is effective in reducing alcohol misuse in patients with moderate to severe psoriasis
O. Founta, K. Adamzik, C. Reid, A.M. Tobin, D. Hevey and B. Kirby

P79 Traditional antiseptics show ineffective antistaphylococcal bactericidal activity
C. Reid, A. Singh and D. Panas

P80 Distinguishing between bioequivalence and bioavailability: the pitfalls of switching brands in ciclosporin prescribing
E. Lashford, S. Das and B.P. Walker

P81 Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy vs. oral minocycline in patients with active vitiligo vulgaris
A. J. Kanwar, A. Singh and D. Panas

P82 Evaluation of the bactericidal activity of an antiseptic emollient wash formulation against Panton-Valentine leucocidin-producing Staphylococcus aureus
L. Gallagher, P. Broshe, J. Leeming and A. Hidalgo-Arroyo

P83 White’s tar paste as an outpatient-based treatment for psoriasis
K. F. Eustace, F. Carroll, A. Kavanagh, B. Kirby, P. Collins and A. Lally

P84 Analgesia requirements in toxic epidermal necrolysis: unmeasured and unmet?
B. Moriarty, R. Lamb, A. Durack, C. May, C. Smith, D. Creamer and S. Walsh

P85 Long term prophylactic management of hereditary angio-oedema, a rare but important cause of referrals to dermatology
J. Kassim and C. Grattan

P86 Our experience of transient elastography and Fibrotest® in monitoring patients taking methotrexate for psoriasis
M. Lynch, E. Higgins, P.A. McCormick, B. Kirby, A. Lally, S. Rogers, A. Yellinga, H. Omar and P. Collins

P87 Therapy with rituximab for pemphigus and pemphigoid: a retrospective study of 103 patients
K. Heelan, S.R.A. Walsh and N.H. Shear

P88 A prospective, double-blind, randomized controlled trial of folic acid supplementation vs. placebo in patients with chronic plaque psoriasis treated with methotrexate and effects on serum homocysteine
## Old Age, New Evidence in Dermatology

New, exciting evidence in older patients will be discussed with our ‘Question Time’ style expert panel including:

- **Hosted by Michael Barratt** (writer, journalist and a former BBC television presenter)
- **Professor Michael Cork**  
  Dermatologist, University of Sheffield
- **Professor Eggert Stockfleth**  
  Dermatologist, Charité - Universitätsmedizin Berlin
- **Professor Peter Passmore**  
  Ageing and Geriatric Medicine, Queen’s University Belfast
- **Sheila Robertson**  
  Dermatology Liaison Nurse Specialist

## Hyperpigmentation – Facing the Challenge

**Chair:** Dr Yuliya Zielinski

- **The cosmetic use of skin lightening agents: merits, challenges and controversies!**  
  Dr Ophelia Dadzie, London
- **4-n-butylresorcinol: a highly effective tyrosinase inhibitor that reduces hyperpigmentation**  
  Dr Ludger Kolber, Hamburg

## Treating the Whole Patient: The Joint Approach

- **Chairs:** Dr Sarah Jarvis, resident Doctor on TV’s the One Show
- **Panel members:**  
  - Dr Ruth Murphy, Dermatologist, Nottingham
  - Dr Ira Pandc, Rheumatologist, Nottingham
  - Dr Mark Goodfield, Dermatologist, Leeds
  - Prof Dennis McGonagle, Rheumatologist, Leeds
  - Dr Tony Downs, Dermatologist, Exeter
  - Dr Richard Haigh, Rheumatologist, Exeter

## Current Controversies in the Management of Actinic Keratoses Debate

- **Chair:** Dr Colin Fleming, Dundee
- **Welcome, Introduction & Audience Voting**  
  Dr Colin Morton
- **1st Proposer:** Treat the entire field - clinical and sub-clinical lesions  
  Professor Eggert Stockfleth, Berlin
- **1st Opposer:** Treat what you see or should you treat at all?  
  Professor Rino Cerio, London
- **2nd Proposer:**  
  Dr Chris Bower, Exeter
- **2nd Opposer:** Dr Jonathan Bowling, Oxford
- **Conclusions & Audience Voting**  
  Dr Colin Fleming
### Refining our approach to the management of psoriatic disease

- Are you interested in changing clinical practice and improving the psoriatic patient pathway?
- Do you want to help develop practical tools to overcome some of the challenges we face in joint dermatology-rheumatology working?

Join a distinguished multidisciplinary faculty in this brainstorm as we begin to develop a simple useable tool to facilitate collaborative working in line with NICE guidelines and Quality Standards.

**Faculty**

- **Dr Richard Warren**  
  Dermatologist (Manchester)

- **Dr Joyce Leman**  
  Dermatologist (Glasgow)

- **Dr Hector Chinoy**  
  Rheumatologist (Manchester)

- **Dr Laura Coates**  
  Rheumatologist (Leeds)

---

### Psoriasis in depth: A stratified approach to treating psoriasis

**CHAIRS:**  
Professor Nick J Reynolds, Institute of Cellular Medicine, Newcastle University, UK.

**Right patient, right drug, right time**  
Dr Richard Warren, Salford Royal Foundation Hospital, UK  
*Dr Warren assesses the potential of personalised treatment to overcome the limitations of current therapies.*

**The role of IL-17 in psoriasis and inflammatory arthritides**  
Dr David Lee, Novartis Institutes for BioMedical Research, Basel, Switzerland.  
*Dr Lee considers recent immunological research and insights that could lead to new therapeutic targets.*

**Audience questions**  
Professor Nick J Reynolds.  
The panel share their experience and answer questions from the audience.

---

**Picato®, Actinic Keratosis (AK)* and the Patient**

**Current therapies for AK patients in the UK**  
Dr John Lear, Consultant Dermatologist, Manchester Royal Infirmary and Hope Hospital, Salford

**Picato® within AK* treatment**  
Dr Sandeep Cliff, Consultant Dermatologist and Dermatological Surgeon, East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust

**The Picato® patient experience**  
Dr Tony Downs, Consultant Dermatologist, Royal Devon and Exeter NHS Foundation Trust

**Question and answer session**  
Dr John Lear

**Picato® is licensed for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.**
**Abbott Healthcare**

**Stand Number:** 31

Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, SL6 4XE

Phone: 01628 773 355

Contact: Chris Barton

Email: christopher.barton@abbvie.co.uk

www.abbvie.com

**ABBVie (NYSE:** ABBV **)** is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. ABBVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

In 2013, ABBVie will employ approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com

---

**Activa Healthcare**

**Stand Number:** 80

1 Lancaster Park, Needwood, Burton on Trent, DE13 9PD

Phone: 01283 576 800

Contact: Nick Haynes

Email: nickhaynes@activahealthcare.co.uk

www.activahealthcare.co.uk

When Activa Healthcare launched the new debridement product, DebrisoFast®, they warned nurses to ‘prepare to be amazed’. In fact, ‘prepare to be amazed’ has proven to be an understatement!

"Works like magic", "Incredible results", and "Absolutely outstanding" are just some of the reactions after using DebrisoFast®.

Are you PREPARED to visit Activa’s Stand?

---

**Alliance Pharmaceuticals Ltd**

**Stand Number:** 17

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BS

Phone: 01249 466 966

Contact: Laura Burgess

Email: info@alliancepharma.co.uk

www.hydromol.co.uk / www.alliancepharma.co.uk

The Hydromol® range of products includes ointments (3 in 1), creams and bath additives. These products are principally used in the UK to treat common dry skin conditions such as Eczema and Psoriasis. These products are SLS free and can be used individually, or together as a Complete Emollient Therapy regime.

---

**Almirall Ltd**

**Stand Number:** 68

1 The Square, Stockley Park, Uxbridge, UB11 1TD

Phone: 020 7160 2500

Contact: Natalie Marley, Margarita Pfarre, Samantha Howell

Email: info.uk@almirall.com

www.almirall.com

Almirall is an international pharmaceutical company with the primary purpose to provide valuable medicines to you and future generations. With headquarters in Barcelona, Spain, Almirall have a strong international interest in Dermatology and research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people’s health and wellbeing.

---

**Aneurin Bevan Health Board Academic Dermatology**

**Stand Number:** 6

St Woolos Hospital, Academic Dermatology, Block C, Newport, NP20 4SZ

Phone: 01249 466 966

Contact: Laura Burgess

Email: info@alliancepharma.co.uk

www.alliancepharma.co.uk

Dermatology training, education and research through patient involvement.

---

**Athrodax Healthcare International Ltd**

**Stand Number:** 33

Hawthorn Business Park, Drybrook, Gloucestershire, GL17 9HP

Phone: 01594 544 440

Contact: Vivien Johnson

Email: sales@athrodax.co.uk

www.athrodax.co.uk

Since 1976, Athrodax have supplied, serviced and maintained Waldmann UV therapy systems, exclusively throughout the UK and Ireland.

We can supply the largest product range to suit all needs and budgets from whole body and partial treatment systems to hand and foot treatment systems.

---

**British Association of Dermatologists Biologic Interventions Register (BADBIR)**

**Stand Number:** 53

BADBIR, The University of Manchester, Rutherford House (Unit 1 F), Manchester Science Park, 40 Pencroft Way, Manchester, M15 6SZ

Phone: 0161 306 1896

Contact: Kathleen McElhone - BADBIR Coordinator

Email: badbir@manchester.ac.uk

www.badbir.org

The BADBIR is a national register of patients receiving therapy for the treatment of moderate to severe psoriasis in the UK. Data is collected on patients treated with biologic or other systemic treatments (for control purpose). The primary aim of the register is to monitor the safety of biologic agents.

---

**BAD Communications**

**Stand Number:** 74

Willan House, 4 Fitzroy Square, London, WIT SHQ

Phone: 0207 3916094

Contact: Dr Nick Levell

Email: nick.levell@mnuh.nhs.uk

www.bad.org.uk

---

**BAD Historical Collection**

**Stand Number:** 44

Willan House, 4 Fitzroy Square, London, WIT SHQ

Contact: Dr Nick Levell

Email: nick.levell@mnuh.nhs.uk

www.bad.org.uk

---

**BAD Journals**

**Stand Number:** 63a

Willan House, 4 Fitzroy Square, London, WIT SHQ

Phone: 0207 391 6346

Contact: John Caulfield, Editorial Manager

Email: john@bad.org.uk

www.bad.org.uk

---

**Bayer Healthcare plc**

**Stand Number:** 42

Bayer House, Strawberry Hill, Newbury, RG14 1JA

Phone: 01635 563147

Contact: Maya Vlahovic

Email: maya.vlahovic@bayer.com

www.canespro.co.uk

Canespro® Fungal Nail Treatment Set - New & unique fungal nail treatment using keratolytic properties of 40% urea ointment. Treat for only 2-3 weeks to get rid of the infected parts of the nail. Follow-up treatment with an antifungal cream is recommended after treatment with Canespro is completed.

---

**Bristol-Myers Squibb**

**Stand Number:** 10

330 Solihull Parkway, Birmingham Business Park, Birmingham, B37 7YB

Phone: 0121 386 8433

Contact: Roger Tyler, Managing Director

Email: sales@blickmedical.com

www.blickmedical.com

Blink Medical was established in 2004 as the world’s first dedicated manufacturer of high quality, single use surgical instruments. We supply instrumentation to many of the UK’s leading dermatology departments and with a worldwide distribution network, covering 15 countries we are leaders in design, development and manufacture of fine instrumentation and customised instrument sets.

Visit us at stand 26.

---

**CanaePro**

**Stand Number:** 28

Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB1 1DH

Phone: 07531 976 705

Contact: Christina Cockley

Email: christina.cockley@bons.com

At Bristol-Meyers Squibb, we are committed to finding innovative medicines to combat serious diseases, and to getting them to patients in the UK and worldwide faster and more efficiently. We have a strong legacy in discovering and developing cancer medicines dating back 40 years and our researchers continue pursuing new strategies to answer the unmet needs of patients has resulted in the emergence of a robust pipeline of anti-cancer agents. Identification of specific targets has facilitated the creation of molecules designed for their potential to inhibit tumour growth, survival and metastasis.

In the next few years, we hope that our decades of cancer research will result in the development of innovative medicines to fight aggressive and previously drug-resistant tumours.
EXHIBITOR DIRECTORY

British Skin Foundation
Stand Number: 32
Willan House, 4 Fitzroy Square, London, W1T SQH
Tel: 0207 391 6341
Email: admin@britishskinfoundation.org.uk
www.britishskinfoundation.org.uk

The British Skin Foundation is the only UK based charity dedicated to funding research into all skin diseases.

Brymill Cryogenic Systems (UK) Ltd
Stand Number: 27
54 Mayfield Ridge, Basingstoke, RG22 4RS
Tel: 01256 841 045
Contact: Steve Williams
Email: sales@brymilluk.com
www.brymill.co.uk

Brymill Cryogenic Systems has been the world leader in the design and manufacture of the Cryosurgical equipment for over 40 years. Brymill UK now supplies a wider range of quality products including Ethicon Sutures, Electroscopy, HeadLights, Binocular Loupes, Dermatoscopes, Single Use Disposable Instruments, Woundcare Products and Smoke Evacuation systems. And introducing the Swift Microwave Generator.

Celvegin Ltd
Stand Number: 20
1 Longwalk Road, Stockley Park, Hillingdon, UB11 1DB
Tel: 0208 831 8300
Contact: Tim Shaw
www.celvegin.com

Celvegin Corporation is a global biopharmaceutical company that is helping healthcare providers address serious conditions, such as cancer and immune-inflammatory diseases. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programmes. Together, these aspects form the core of our commitment to patients worldwide.

Clinical Services Unit
Stand Number: 63b
Willan House, 4 Fitzroy Square, London, W1T SQH
Tel: 020 7391 6085
Contact: Tania von Hospenthal
Email: clinical@bad.org.uk
www.bad.org.uk

Clinique Laboratories LLC
Stand Number: 64
73 Grosvenor Street, London, W1K 3BQ
Tel: 020 7391 6085
Contact: Julia Cox
Email: jcox@estee-lauder.co.uk
www.cliniquederms.com

Allergy Tested. 100% Fragrance Free. Dermatologist Developed

Clinisupplies Ltd
Stand Number: 22
Qualitas House, 100 Elm Grove Rd, Harrow, Middlesex, HA1 2RW
Tel: 0208 863 4168
Contacts: Rishi Doshi / Ade Akindeinde
Email: marketing@clinisupplies.co.uk
www.clinisupplies.co.uk

Established in 2000, Clinisupplies is a UK based medical devices company specialising in the manufacturing and marketing of products for the primary and secondary healthcare sectors. Clinisupplies is supported by dedicated and experienced employees with a deep understanding of the medical devices market. The result is a reputation of providing high quality medical devices that are fully compliant with strict UK Specifications.

Community Dermatology & IFD
Stand Number: 63c
Willan House, 4 Fitzroy Square, London, W1T SQH
Tel: 0207 391 6346
Contact: John Caulfield
Email: john@bad.org.uk
www.bad.org.uk

Crawford Healthcare Ltd
Stand number: 13
King Edward Court, King Edward Rd, Knutsford, Cheshire, WA16 0BE
Tel: 01565 659420
Contact: Karen Kennedy
Email: info@crawfordpharma.com
www.crawfordhealthcare.com

Crawford Healthcare, is a supplier of dermatology and wound care products covering a broad range of skin conditions. We are dedicated to developing and providing innovative treatment solutions to care and repair the skin, helping healthcare professionals to maintain our number one natural defense system.

Cynosure UK Ltd
Stand number: 25
The Old Barn Offices, Lower Mount Farm, Long Lane, Cookham, Berkshire, SL6 9EE
Tel: 01628 522 252
Email: jenny@cyonosureuk.com
www.cynosureuk.com

Contact: Ben Saviger-Jones / Jenny Flood
Cynosure UK Ltd’s modular lasers are market leading products offering the ultimate technology for applications such as hair removal in all skin types, skin rejuvenation, tattoo removal, treatment of pigmented/vascular lesions including facial and leg veins. Our range includes the more invasive treatments such as laser lipolysis, surgical cellulite clearance and fractional rejuvenation.

Derma UK Ltd
Stand Number: 34
ARC Progress, Mill Lane, Stotfold, Bedfordshire, SG9 4NY
Tel: 01462 733 500
Contact: Phil Carroll
Email: info@derma.co.uk
www.derma.co.uk

Derma UK is dedicated to the provision of high quality and cost-effective dermatological preparations to dermatologists, nurses and other medical Practitioners in the UK. Please come and visit our stand to discuss how we may be able to assist in generating some cash savings on your prescribing budgets.

Dermal Laboratories Ltd
Stand Number: 58
Tatmore Place, Gosmore, Hitchin, SG4 7QR
Tel: 01462 458 866
Contact: Me Henrik Pyff
Email: info@dermal.co.uk
www.dermal.co.uk

2013 sees Dermal celebrate 50 years of successful topical innovation. This extensive experience in developing highly effective, yet cosmetically elegant treatments for application to the skin, has benefitted millions of people for half a century. Come and visit us on Stand 58 to hear more about our products and dermatology services.

Dexcil Pharma Ltd
Stand Number: 54
7 Sopwith Way, Drayton Fields Industrial Estate, Daventry, Northants, NN11 8BP
Tel: 01327 316 858
Contact: Rob Callum
Email: dexcilpharma@live.co.uk
www.dexcilpharma.co.uk

Dexcil Pharma Ltd is the manufacturer of Desimune®, an alternative brand of ciclosporin which is bioequivalent to the leading brand whilst offering significant savings. Dexcil Pharma Ltd specialises in the discovery, development, manufacture and marketing of innovative formulations of successful, established, prescription drug molecules. Dexcil Pharma offers significant savings to the NHS.

Dilagenics Ltd
Stand Number: 36
South House 3, Bond Avenue, Betchley, Milton Keynes, MK1 1SW
Tel: 01908 376 376
Contact: Jim Khambatta
Email: info@dilagenics.co.uk
www.dilagenics.co.uk

Dilagenics will be showing the truetest patch test system, which allows the rapid application of 34 pre-dispensed patches and also Allegraase, a comprehensive system of petrolatum allergens, it chambers and newly introduced Patchmap and Patchprotect to ensure the security of application of the chambers and the identity of the allergens.

Dr. Hönle Medizintechnik GmbH
Stand Number: 48
Viktor-Frankl-Strasse 20, 86916 Kaufering, Germany
Tel: +49-8191-30555-0
Contact: Petra Kleinhaus
Email: medizin@hohonle.de
www.drhonenle.de

Dr. Hönle Medizintechnik is specialized in the sales and service of high-quality UV irradiation devices for the treatment of skin conditions. The company also sells iontophoresis units for the treatment of Hyperhidrosis. Thanks to ongoing exchanges of ideas and experiences with patients and partners we are constantly improving our products.

DreamSkin Health Ltd
Stand number: 37
The Melon Ground, Hatfield Park, Hatfield, Hertfordshire, AL9 5NB
Tel: 01707 228 688
Contact: Tony Wilson
Email: tony.wilson@dreamskinhealth.co.uk
www.dreamskinhealth.co.uk

Therapeutic clothing that provides symptomatic relief for sufferers of eczema.

• Retains Moisture: Reduces the unregulated loss of moisture caused by evaporation from damaged skin.

• Repels Irritants: Forms a barrier that prevents irritants from reaching the skin.

• Maintains Temperature Regulation: Restores the skin’s natural temperature management process.

First Medical Staffing Solutions Ltd
Stand Number: 45
1.10 Challenge House, Sherwood Drive, Bletchley, Milton Keynes, MK3 6DP
Tel: 01908 533245
Contact: Lawrence Alexander
Email: Lawrence.Alexander@first-medical.co.uk
www.first-medical.co.uk

First Medical Staffing Solutions are the leaders in Dermatology Solutions for the NHS Hospitals. If you are a dermatologist and interested in a variety of full time, part time or ad hoc opportunities please register with us today! Or if your dermatology department could use extra help, please visit our stand.

Forest Laboratories UK Ltd
Stand Number: 60
Riverbridge House, Anchor Boulevard, Crossways Business Park, Dartford, DA2 6SL
Tel: 01322 421800
Email: info@forest-labs.co.uk
www.forest-labs.co.uk

Forest Laboratories UK Limited sells prescription medicines and branded pharmaceutical products sold over-the-counter (OTC). Exorex Lotion (Coal tar solution 5% w/v & cutaneous emulsion) is a clinically proven treatment for psoriasis.
Intrapharm Laboratories Ltd
Stand number: 46
The Granary, The Courtyard Barns, Choke Lane, Cookham Dean, Maidenhead, Berkshire, SL6 6PT
Tel: 01628 771800
Contact: Sunil Shauvak
Email: Sunil@intrapharmlabs.com
www.intrapharmlabs.com
Intrapharm have re-launched Terra-Cortil Ointment for exudative and secondarily infected eczema including atopic eczema, primary irritant dermatitis, allergic and seborrhoeic dermatitis. Terra-Cortil is a combination of two components - oxytetracycline and hydrocortisone. It does not contain any preservatives. Please visit our stand 46.

Janssen
Stand Number: 70
50-100 Holmers Farm Way, High Wycombe, Bucks, HP12 4GC
Tel: 01494 567 567
Contact: Raquel Alcobia
Email: ralco@itv.ljnc.com
www.janssen.co.uk
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. Janssen is part of the Johnson & Johnson family of companies and is committed to delivering innovative treatments that can make an important difference to the lives of patients with serious health conditions.

Johnson & Johnson Ltd
Stand Number: 71
Foundation Park, Roxborough Way, Maidenhead, SL6 3UG
Tel: 01628 822222
Contact: Rebecca Bennett
Email: rbenne@itv.ljnc.com
www.jnj.com

LEO Pharma
Stand Number: 14
Longwick Road, Princes Risborough, Bucks, HP22 9RR
Tel: 01844 347 333
Email: general.uk@leo-pharma.com
www.leo-pharma.co.uk
LEO Pharma is a global pharmaceutical company dedicated to helping people achieve healthy skin. Headquartered in Denmark, with 4,600 employees in 61 countries our dermatological and thrombosis products are sold in over 100 countries. Being owned by the LEO Foundation, with no external shareholders, profits are re-invested to benefit patients.
Leo® ©Leo Pharma, UK. All Leo trademarks mentioned belong to the Leo Group.

London Dermatopathology
Stand Number: 41
50 Belize Square, London, NW3 4HN
Tel: 020 8090 5802
Contact: Dr Alistair Robson / Mr Cameron Niven
Email: operations@ldpath.com
www.ldpath.com
• Premium specialist reporting by a team of 10 dermatopathologists
• Competitive flat fee structure (up to 7 specimens)
• Courier collection anywhere in the UK
• Reports delivered securely by email and via SSL-encrypted website
• 24-48hr turnaround
• Second opinion from expert panel
• Privileged access to educational material

Galderma (UK) Ltd
Stand Number: 11
Meriden House, 69-71 Clarendon Road, Watford, WD17 1DS
Tel: 01923 208 950
Email: info.uk@galderma.com
www.galderma.com
500 employees worldwide contribute to this success.

Genus Pharmaceuticals Ltd
Stand number: 66
Park View House, 65 London Road, Newbury, Berkshire, RG14 1JN
Tel: 01635 568 400
Contact: Eric Sharp
Email: info@genuspharma.com
www.genuspharma.com
Genus Pharmaceuticals is a medium sized pharmaceutical company committed to providing quality healthcare products and services, focusing on specialised therapy areas, providing a responsive and friendly service to our customers whilst helping to ensure a positive difference for patients. Our expertise lies in Dermatology and Parkinson’s Disease, substance misuse and tuberculosis.

H&R Healthcare Ltd
Stand Number: 7
3 Redcliff Road, Melton Park, Melton, Hull, HU14 3RS
Tel: 01482 631606
Contact: Mike Hoskins
Email: info@hrhealthcare.co.uk
www.hrhealthcare.co.uk
H&R Healthcare distribute dermatologically advanced products for wound, skin and scar care. Sorbion sana: highly absorbent, non-adherent dressing for sensitive skin Proshield: the only barrier cream indicated for intact and injured skin associated with incontinence. BAP scar care: a comprehensive range of scar care products. The gel leaves a non-shiny matt finish ideal for use under make-up.

HEINE Optotechnik
Stand Number: 85
Kienstallere 7, 82211 Herrsching, Germany
Tel: +49 (0) 8152 – 380
Contact: Mr Werner Krutsch
Email: info@heine.com
www.heine.com
HEINE Optotechnik. Founded in 1946, family owned and today the world’s largest exporter of primary, hand-held diagnostic instruments. HEINE products meet all international standards (ISO/CE). Research and development has created a solid and diverse technology base for continued quality and product leadership. Over 500 employees worldwide contribute to this success.

Intrapharm Laboratories Ltd
Stand number: 46
The Granary, The Courtyard Barns, Choke Lane, Cookham Dean, Maidenhead, Berkshire, SL6 6PT
Tel: 01628 771800
Contact: Sunil Shauvak
Email: Sunil@intrapharmlabs.com
www.intrapharmlabs.com
Intrapharm have re-launched Terra-Cortil Ointment for exudative and secondarily infected eczema including atopic eczema, primary irritant dermatitis, allergic and seborrhoeic dermatitis. Terra-Cortil is a combination of two components - oxytetracycline and hydrocortisone. It does not contain any preservatives. Please visit our stand 46.

Janssen
Stand Number: 70
50-100 Holmers Farm Way, High Wycombe, Bucks, HP12 4GC
Tel: 01494 567 567
Contact: Raquel Alcobia
Email: ralco@itv.ljnc.com
www.janssen.co.uk
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. Janssen is part of the Johnson & Johnson family of companies and is committed to delivering innovative treatments that can make an important difference to the lives of patients with serious health conditions.

Johnson & Johnson Ltd
Stand Number: 71
Foundation Park, Roxborough Way, Maidenhead, SL6 3UG
Tel: 01628 822222
Contact: Rebecca Bennett
Email: rbenne@itv.ljnc.com
www.jnj.com

LEO Pharma
Stand Number: 14
Longwick Road, Princes Risborough, Bucks, HP22 9RR
Tel: 01844 347 333
Email: general.uk@leo-pharma.com
www.leo-pharma.co.uk
LEO Pharma is a global pharmaceutical company dedicated to helping people achieve healthy skin. Headquartered in Denmark, with 4,600 employees in 61 countries our dermatological and thrombosis products are sold in over 100 countries. Being owned by the LEO Foundation, with no external shareholders, profits are re-invested to benefit patients.
Leo® ©Leo Pharma, UK. All Leo trademarks mentioned belong to the Leo Group.

London Dermatopathology
Stand Number: 41
50 Belize Square, London, NW3 4HN
Tel: 020 8090 5802
Contact: Dr Alistair Robson / Mr Cameron Niven
Email: operations@ldpath.com
www.ldpath.com
• Premium specialist reporting by a team of 10 dermatopathologists
• Competitive flat fee structure (up to 7 specimens)
• Courier collection anywhere in the UK
• Reports delivered securely by email and via SSL-encrypted website
• 24-48hr turnaround
• Second opinion from expert panel
• Privileged access to educational material

L. Oreal – La Roche Posay
Stand Number: 69
255 Harrowby Road, London, W6 8AZ
Tel: 07554 116 971
Email: jatyfor.3hluk@loreal.com
Contact: Juliette Taylor
Recommended by over 25,000 dermatologists. Sensitive skin specialist.
Launched in 2009 in the UK, La Roche-Posay is committed to Dermatology offering a wide range of adjunctive therapy products for the main reasons of consultation in Dermatology practice.
Since 2009 La Roche-Posay has achieved great success with the launch of Anthelios XL, the highest SPF rated photo protection, which is also now available on prescription.
We support patient and professional education events together with extensive research in the field of Dermatology.

Meda Pharmaceuticals Ltd
Stand Number: 19
Skyway House, Panonage Road, Takeley, Bishop’s Stortford, CM22 6PU
Tel: 0845 460 0000
Email: info@medapharma.co.uk
www.meda-psm.com
At Meda, we’re constantly evolving our impressive product range. In the UK we currently have over 70 products, including many well-known prescription, pharmacy and cosmetic brands.
Our ever-expanding product portfolio covers a wide range of treatment areas from allergy, cardiology and dermatology, to oncology and sexual health.
Within Dermatology we have just launched Zyclara 3.75% Imiquimod Cream for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding.

Medac GmbH
Stand number: 47
Scicon House, Stirling University Innovation Park, Stirling, FK9 4NF
Tel: 01786 458 086
Email: info@medac-uk.co.uk
www.medac-uk.co.uk
medac is a German based pharmaceutical manufacturer with a growing number of branches around the world.
Metopet (metoprolxate injection 50 mg/ml) was launched by medac and is indicated for the treatment of severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy.

Mölnlycke Health Care
Stand Number: 55
Arendsen Centre, Arentson Way, Dunstable, Bedfordshire, LU5 4UL
Tel: 0800 7311 876
Email: info.uk@molnlycke.com
www.molnlycke.co.uk
Mölnlycke Health Care manufactures and markets a range of dermatology products for eczema, psoriasis and other dry skin conditions including. Epaderm® Ointment, Epidam® Cream and Tubifast® Garments.
Mölnlycke offers a product portfolio with which to meet the needs of health care professionals in hospitals and primary care organisations.

MSD (Diprobate)
Stand number: 61
Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU
Tel: 01992 455 423
Contacts: Ellen Edwards, James Cotterell, Julie Dixon
Email: julie.dixon@merck.com
www.diprobate.co.uk
The Diprobate emollient range has been patient friendly for 30 years. The formulations are tried and trusted making it the UK’s number 1 most GP prescribed emollient. Diprobate is an MSD – Consumer Care product.
Today’s MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.

Novartis Pharmaceuticals UK Ltd
Stand Number: 65
200 Frimley Business Park, Frimley, Surrey, GU16 7SR
United Kingdom
www.novartis.co.uk
At Novartis, our goal is to provide high quality healthcare solutions to address the evolving needs of patients and society in the UK.
We believe that our dedication to innovation and our responsible approach will enable us to fulfil our mission to care for and provide high quality treatments for people with psoriasis.
SRSKPHARMA Ltd
Stand Number: 52
335 City Road, London, EC1V 1LJ
Tel: 020 3919 1916
Contact: Dr Hamdideha Khabtarabi
Email: info@srskpharma.co.uk
www.srskpharma.co.uk

Dexem® Repair is a product line designed based on patented natural Bioactive complex to block harmful bacteria from attacking the irritated skin and targets the symptoms of eczema and other forms of irritated skin. This steroid-free product allows the irritated and eczematous skin to recover naturally without the constant stress from external factors. Dexem Repair has been dermatologically tested and suitable to use on children.

Schuco
Stand Number: 62
Axis 4, Rhodes Way, Watford, WD24 4YW
Tel: 020 8368 1642
Contact: James Watson
Email: james.watson@schuco.co.uk
www.schuco.co.uk

At Schuco you’ll find tomorrow’s skin technology, today!

Share our passion and expertise for innovative medical devices for dermatology and aesthetics including; imaging, detection and management of a variety of conditions from early detection of skin cancer to minor surgery and PRP (Platelet-Rich-Plasma).

SilDerm Ltd
Stand Number: 77
DaneMill, Broadhurst Lane, Congleton, Cheshire, CW12 1LA
Tel: 01260 271666
Contact: Aileen Cameron
Email: aileen@silderm.com
www.silderm.com

The development of all SilDerm’s products is based on sound scientific and medical research and all products have proven effectiveness. The recent addition of our scar gel and spray range leads the way in the management of scars and burns.

Stiefel, a GSK company
Stand Number: 15
GlosSmithKline, Stockley Park West, 1-3 Iron Bridge Road, Uxbridge, UB8 1BT
Tel: 0208 990 9000
Contact: Geoff Holmes
Email: Geoff.d.holmes@stiefel.com
www.stiefel.com

Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel’s dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as a world leader in the skin health industry.

To learn more about Stiefel, visit www.stiefel.com.

Spirit Healthcare
Stand Number: 56
Spirit House, Selbury Drive, Gaddes, Leicester, LE2 5NG
Tel: 01162 865000
Contact: Angelina Thorne
Email: angelinath@spirit-healthcare.co.uk
www.spirit-healthcare.co.uk

Spirit Healthcare (STAND 56) is dedicated to helping you improve patient outcomes, expanding treatment choices and maximising productivity. We have launched a new range of Photodynamic Therapy products including Ameluz® 5-aminolaevulinic acid gel licensed ALA, the BF-RhodoLED® static lamp, and Ambilight ambulatory light source. Spirit Healthcare: A brighter future in dermatology.

STD Pharmaceuticals
Stand Number: 49
Plough Lane, Hereford, HR4 0EL
Tel: 01432 373555
Contact: Julie Halford
Email: enquiries@stdpharm.co.uk
www.ioptophoresis.info
STD are the suppliers of iontophoresis machines worldwide and provide machines for hospitals & patients throughout the UK.

Julie Halford from the Hyperhidrosis Support Group provides a one-off training session on Hyperhidrosis and the use of iontophoresis machines within the hospital environment. For further details please contact her at the Hyperhidrosis Support Group: info@hyperhidrosisuk.org

Typharm Ltd
Stand Number: 3
14D Wendover Road, Rackheath Industrial Estate, Norwich, NR13 6LU
Tel: 01603 722 480
Contact: Shaua Clark
Email: shaunaclark@typharm.co.uk
www.typharm.com

Typharm Ltd is a UK company that specialises in marketing a range of pharmaceutical products for the treatment of various inflammatory and non-inflammatory skin conditions. Products include Hexalen Tape, a moderately potent steroid, presented in an occlusive tape for the treatment of recalcitrant dermatoses including eczema, heel and finger fissuring as well as overgranulation.

Wiley
Stand Number: 24
1 Oldway Courts, Bognor Regis, West Sussex, PO22 9SA
Tel: 01243 843 294
Contact: Customer Service Department
Email: customer@wiley.com
www.wiley.com

Wiley is an international scientific, technical, medical and scholarly publisher with over 1,400 peer-reviewed journals and 1,500+ new books annually in print and online. Wiley publishes the BAD’s journals, the British Journal of Dermatology and Clinical and Experimental Dermatology.

Wisepress Medical Bookshop
Stand Number: 23
25 High Path, Merton Abbey, London SW19 2JL
Tel: 020 8715 1812
Contact: Nadia Ahmed
Email: bookshop@wisepress.com
www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a complete range of relevant books and journals which can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. We also have a comprehensive medical and scientific online bookshop with great offers.

World Congress on Cancers of the Skin 2014
Stand Number: 43
WCCS 2014, Conference & Event Services, 4 Fitzroy Square, London, W1T 1HQ
Tel: 020 7391 6343
Email: wccs2014@bad.org.uk
www.wccs2014.com

The World Congress on Cancers of the Skin (WCCS 2014) will allow physicians a unique opportunity to interact with a distinguished international faculty and learn about breakthrough discoveries in the prevention, diagnosis, and treatment of all types of skin cancer.
Delegate Bags

The Conference & Events Department is aiming to limit the impact the Annual Meeting has upon the environment. Conferences and exhibitions provide a huge amount of waste and this year we aim to continue to implement measures to improve this. Following feedback from previous meetings delegates will be provided with a generic delegate bag (as illustrated). This bag is made from recycled plastic bottle and has the BAD Logo on the side. We have made a decision not to include a sponsor, date or annual meeting destination. This will enable you to reuse the bag for other annual meetings as well as other BAD meetings. We hope this will become your BAD ‘Bag for Life’. If you have a bag from a previous annual meetings please bring it with you.

Evaluation Form

This year’s evaluation form will be on-line and all attendees will be sent a link after the meeting. Thank you in advance for taking the time to complete it, as it is an invaluable tool for us in organising future meetings.

Delegate Bags
The Conference & Events Department is aiming to limit the impact the Annual Meeting has upon the environment. Conferences and exhibitions provide a huge amount of waste and this year we aim to continue to implement measures to improve this. Following feedback from previous meetings delegates will be provided with a generic delegate bag (as illustrated). This bag is made from recycled plastic bottle and has the BAD Logo on the side. We have made a decision not to include a sponsor, date or annual meeting destination. This will enable you to reuse the bag for other annual meetings as well as other BAD meetings. We hope this will become your BAD ‘Bag for Life’. If you have a bag from a previous annual meetings please bring it with you.

Evaluation Form
This year’s evaluation form will be on-line and all attendees will be sent a link after the meeting. Thank you in advance for taking the time to complete it, as it is an invaluable tool for us in organising future meetings.

Don’t forget your bag!

For Further Details on any of these meetings please contact:
• Conference & Event Services; 4 Fitzroy Square London W1T 5HQ
• Email: conference@bad.org.uk
• Tel: 020 7391 6358

MAP OF LIVERPOOL

Location Key

1. Arena and Convention Centre
2. Atlantic Tower by Thistle
3. Base2Stay Liverpool
4. Bridgewater Worldwide
5. Crowne Plaza Liverpool
6. Days Inn Hotel
7. Express by Holiday Inn
8. Liverpool Premier Inn
9. Hilton Liverpool
10. Hard Days Night Hotel
11. Hotel Indigo
12. Hotel Ibis
13. Hotel Indigo
14. Jurys Inn
15. Malmaison
16. Novotel Liverpool Centre
17. Radisson Blu Hotel
18. Staybridge Suites
19. Signum Hotel
20. Carlton Hotel
21. The Athenaeum
22. Gusto Restaurant and Bar
23. Blue Bar
24. St George’s Hall

CES MEETINGS CALENDAR

SEPTEMBER 2013
DermDoc
Venue: Willan House, London
Date: 30th September

OCTOBER 2013
Clinical Dermatology Update Meeting for Staff and Associate Specialist Doctors
Venue: Radisson Blu
Manchester Airport Hotel
Date: 10th – 11th October

Teledermatology Forum
Venue: Willan House, London
Date: 17th October

NOVEMBER 2013
SpR Training Event
Venue: Willan House, London
Date: 7th – 8th November

British Cosmetic Dermatology Group (BCDG)
8th Annual Meeting
Venue: Willan House, London
Date: 9th November

The Annual UK Dermatology Course for Consultants
Venue: Hilton Paddington Hotel, London
Date: 29th – 30th November

Join our Facebook Group: Conference & Event Services from the BAD
Follow us on Twitter @ BritDermEvents

For Further Details on any of these meetings please contact:
• Conference & Event Services; 4 Fitzroy Square London W1T 5HQ
• Email: conference@bad.org.uk
• Tel: 020 7391 6358
XV WORLD CONGRESS ON CANCERS OF THE SKIN

3-6 SEPTEMBER 2014
EDINBURGH, SCOTLAND

Professor John Hawk
Congress President

Professor Alex Anstey
Congress Secretary-General

Supporting Organisations

visit www.wccs2014.org for details